
==== Front
Neurotherapeutics
Neurotherapeutics
Neurotherapeutics
1933-7213
1878-7479
Elsevier

S1878-7479(24)00130-2
10.1016/j.neurot.2024.e00443
e00443
Review
Gene therapy for the leukodystrophies: From preclinical animal studies to clinical trials
Metovic Jasna ab1
Li Yedda ab1
Gong Yi ab
Eichler Florian feichler@mgb.org
ab⁎
a Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
b Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
⁎ Corresponding author. feichler@mgb.org
1 These two authors contributed equally to this work.

13 9 2024
7 2024
13 9 2024
21 4 e0044311 6 2024
22 8 2024
22 8 2024
© 2024 The Authors. Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.
2024

https://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Leukodystrophies are progressive single gene disorders affecting the white matter of the brain. Several gene therapy trials are in progress to address the urgent unmet need for this patient population. We performed a comprehensive literature review of all gene therapy clinical trials listed in www.clinicaltrials.gov through August 2024, and the relevant preclinical studies that enabled clinical translation. Of the approximately 50 leukodystrophies described to date, only eight have existing gene therapy clinical trials: metachromatic leukodystrophy, X-linked adrenoleukodystrophy, globoid cell leukodystrophy, Canavan disease, giant axonal neuropathy, GM2 gangliosidoses, Alexander disease and Pelizaeus-Merzbacher disease. What led to the emergence of gene therapy trials for these specific disorders? What preclinical data or disease context was enabling? For each of these eight disorders, we first describe its pathophysiology and clinical presentation. We discuss the impact of gene therapy delivery route, targeted cell type, delivery modality, dosage, and timing on therapeutic efficacy. We note that use of allogeneic hematopoietic stem cell transplantation in some leukodystrophies allowed for an accelerated path to clinic even in the absence of available animal models. In other leukodystrophies, small and large animal model studies enabled clinical translation of experimental gene therapies. Human clinical trials for the leukodystrophies include ex vivo lentiviral gene delivery, in vivo AAV-mediated gene delivery, and intrathecal antisense oligonucleotide approaches. We outline adverse events associated with each modality focusing specifically on genotoxicity and immunotoxicity. We review monitoring and management of events related to insertional mutagenesis and immune responses. The data presented in this review show that gene therapy, while promising, requires systematic monitoring to account for the precarious disease biology and the adverse events associated with new technology.

Keywords

Leukodystrophies
Gene therapy
Adeno-associated viral vector
Lentiviral vector
Antisense oligonucleotide
==== Body
pmcIntroduction

Leukodystrophies are heritable, progressive disorders that predominantly affect the white matter of the central nervous system (CNS). As a group, the overall incidence is one in approximately 7600 live births [1]. All leukodystrophies affect myelin, the insulation around nerves that enables rapid communication between neurons. Pathologic processes destroy existing myelin (demyelination), trigger abnormal myelin deposition (dysmyelination), or prevent myelin deposition (hypomyelination) in the CNS and/or peripheral nervous system (PNS) during development [2]. Currently, more than 50 disorders are classified as leukodystrophies, and this number continues to grow. Mortality is 34% with an average age at death of 8.2 years [1]. While clinical manifestations can be highly variable even for patients with the same leukodystrophy, disease severity is often inversely correlated with age at disease onset. The most severe forms present in infancy with rapid progression to neurologic devastation and death.

Treatment approaches vary based on pathogenesis, but most fall into one of four categories: 1) enzyme replacement therapies replace the missing or defective enzyme; 2) substrate reduction therapies reduce the buildup of the (often toxic) compound that cannot be adequately metabolized; 3) cell therapies replace diseased cells with healthy allogeneic cells or corrected autologous cells; 4) gene therapies functionally replace the missing or defective gene. In this review, we focus on gene therapies that have reached clinical trials as we aim to understand studies needed to enable leukodystrophy trial readiness. Prior leukodystrophy reviews focus on cellular mechanisms [3] and available clinical trials [4]. Here, we present an updated and comprehensive review of all gene therapy clinical trials for leukodystrophy patients in the context of disease-specific pathophysiology and preclinical studies.

Classification and cellular mechanisms underlying the pathogenesis of leukodystrophies

The definition of leukodystrophies has evolved significantly with advances in next generation sequencing, magnetic resonance imaging (MRI), and molecular biology techniques that together have informed a more nuanced understanding of pathophysiology [3,5,6]. In 2017, van der Knaap and Bugiani [2] proposed a new classification system that grouped leukodystrophies into five categories related to pathologic changes and pathogenic mechanisms (Fig. 1, Table 1). Myelinopathies arise from defects in oligodendrocytes or myelin structure. They are further subcategorized as disorders of hypomyelination, demyelination, and myelin vacuolization which disrupts myelin integrity. Leuko-axonopathies stem from defects in neurons and their axonal processes. Astrocytopathies and microgliopathies disrupt neuroinflammation and CNS repair. Leuko-vasculopathies develop from pathologic processes within the small blood vessels of the brain [2]. Some pathologically relevant CNS cell types, such as microglia, can derive from hematopoietic stem cell precursors with important implications for therapeutic development.Fig. 1 A classification system for leukodystrophies based on cellular mechanisms and pathophysiology, adapted from van der Knaap and Bugiani [2]. This is not a comprehensive list of the leukodystrophies.

Fig. 1

Table 1 List of common leukodystrophies, their associated genes, inheritance, and pathophysiology.

Table 1Disease	Gene affected/cell type	Inheritance	Gain or Loss of Function	Pathophysiology	Predominant cell type(s) affected	
MYELIN DISORDERS	
Demyelination	
X-linked adrenoleukodystrophy	ABCD1	XLR	LOF	Impaired transport of very long chain fatty acids into the peroxisome	Oligodendrocytes, neurons	
Metachromatic leukodystrophy	ARSA	AR	LOF	Impaired lysosomal sulfatide metabolism	Oligodendrocytes, microglia	
Globoid cell leukodystrophy	GALC	AR	LOF	Impaired metabolism of galactosylsphingosine in the lysosome	Oligodendrocytes	
Cerebrotendinous xanthomatosis	CYP27A1	AR	LOF	Impaired cholesterol metabolism	Oligodendrocytes	
Hypomyelination	
Pelizaeus Merzbacher disease	PLP1	XLD	GOF	Accumulation of mutant PLP1 in the endoplasmic reticulum	Oligodendrocytes	
Pelizaeus Merzbacher like-disease	GJC2	AR	LOF	Impaired gap junction formation and cell-cell communication	Oligodendrocytes, astrocytes	
Myelin vacuolization	
Canavan disease	ASPA	AR	LOF	Impaired lysosomal metabolism of N-acetylaspartic acid	Oligodendrocytes	
Cx32-related Charcot-Marie-Tooth disease	GJB1	XLR	LOF	Impaired stabilization of myelin structure, impaired calcium signaling	Oligodendrocytes	
ASTROCYTOPATHIES	
Alexander disease	GFAP	AD	GOF	Toxic accumulation of mutant GFAP, impaired intermediate filament formation	Astrocytes	
Megalencephalic leukoencephalopathy with subcortical cysts	MLC1
HEPACAM	AR
AR/AD	LOF	Abnormalities of cell junctions, impaired astrocyte-astrocyte communication	Astrocytes	
Vanishing white matter disease	EIF2B1; EIF2B2; EIF2B3; EIF2B4; EIF2B5	AR	LOF	Abnormal messenger RNA translation, impaired cellular stress response	Astrocytes, oligodendrocytes	
Aicardi-Goutières syndrome	ADAR
RNASEH2A
RNASEH2B
RNASEH2C
SAMHD1
ATREX1
IFIH1	AR/AD
AR
AR
AR
AR
AR/AD
AD	LOF
LOF
LOF
LOF
LOF
LOF
LOF	Abnormal nucleic acid metabolism
OR abnormal immune system activation	Astrocytes, oligodendrocytes	
Oculodentodigital dysplasia	GJA1	AD/AR	LOF	Abnormal connexin 43 structure, irreversible gap junction closure	Astrocytes, oligodendrocytes	
LEUKOAXONOPATHIES	
TUBB4A-related leukodystrophy	TUBB4A	AD	GOF	Impaired formation and stability of microtubules	Neurons, oligodendrocytes	
Hypomyelination with congenital cataract	FAM126A	AR	LOF	Abnormal myelin synthesis	Neurons	
Gangliosidosis GM1	GLB1	AR	LOF	Impaired lysosomal metabolism of gangliosides	Neurons, oligodendrocytes	
Gangliosidosis GM2	HEXA
HEXB	AR
AR	LOF	Impaired lysosomal metabolism of gangliosides	Neurons	
Pol-III related disorders	POLR3A
POLR3B	AR
AR	LOF	Impaired assembly and function of RNA polymerase III	Neurons, oligodendrocytes	
Hypomyelination with brainstem and spinal cord involvement and leg spasticity	DARS1	AR	LOF	Impaired aspartyl-tRNA synthetase function	Neurons	
Leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation	DARS2	AR	LOF	Impaired aspartyl-tRNA synthetase function in mitochondria	Neurons, astrocytes	
Giant axonal neuropathy	GAN	AR	LOF	Impaired ubiquitin-proteosome function, impaired neurofilament degradation	Neurons	
MICROGLIOPATHIES	
CSF1R-related leukoencephalopathy	CSF1R	AD
AR	LOF (HIS)
LOF	Impaired auto-phosphorylation of CSF1R tyrosine kinase and microglial function	Microglia	
Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (Nasu-Hakola disease)	TYROBP
TREM2	AR
AR	LOF
LOF	Abnormal microglial and osteoclast activation	Microglia	
VASCULOPATHIES	
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy	NOTCH3	AD	GOF	Impaired function and survival of vascular smooth muscle cells	Vascular smooth muscle cells	
Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy	HTRA1	AR	LOF	Abnormal TGFβ signaling, abnormal angiogenesis	Vascular smooth muscle cells	
Abbreviations: AD: autosomal dominant; AR: autosomal recessive; GOF: gain of function; HIS: haploinsufficiency; LOF: loss of function; XLD: X-linked dominant; XLR: X-linked recessive.

Pathogenic mutations in leukodystrophy genes affect integral cellular functions involved in recycling (peroxisomal and lysosomal metabolism), energy production (mitochondrial electron transport), structural integrity (of myelin, cytoskeleton, extracellular matrix, blood brain barrier (BBB), etc.), and protein synthesis (messenger ribonucleic acid (mRNA) transcription and translation), among others. Understanding these pathogenic mechanisms (Fig. 2) is critical in designing successful gene therapies.Fig. 2 Molecular and cellular mechanisms disrupted by leukodystrophy pathophysiology in the setting of the brain tissue microenvironment. Abbreviations: 4H: Hypomyelination with hypogonadotropic hypogonadism and hypodontia or POL-III related disorders; X-ALD: X-linked adrenoleukodystrophy; GLD: Globoid cell leukodystrophy; MLD: Metachromatic leukodystrophy; TSD: Tay-Sachs disease; SD: Sandhoff disease; ADLD: Autosomal dominant leukodystrophy; CD: Canavan disease; ALSP: Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (CSF1R-related leukoencephalopathy); PMD: Pelizaeus-Merzbacher disease; AxD: Alexander disease; CADASIL: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy.

Fig. 2

Therapeutic modalities for gene delivery

The therapeutic efficacy of gene therapies relies heavily on the efficient delivery of nucleic acid to the nucleus. Viral-mediated gene delivery is predominantly used in clinical trials today for its high efficiency and relative safety. The delivery route also impacts therapeutic efficacy and differs for different leukodystrophies and target cell types. In CNS targeting, the need to traverse the BBB is a fundamental obstacle. In the healthy CNS, astrocytes, pericytes, endothelial cells, and other cell types contributing to BBB structural integrity work together to create a controlled and dynamic microenvironment that maintains BBB integrity and CNS homeostasis [7]. While the integrity of a healthy BBB can impede delivery of gene therapy, pathologic neuroinflammation can disrupt the BBB and alter the pharmacokinetics of viral vector penetration of the CNS [8]. For most CNS disorders (Table 2), common routes of delivery for CNS-targeted gene therapies include ex vivo delivery to hematopoietic stem cells (HSCs) [9] and in vivo delivery directly to the CNS [10] through intravenous (IV), intracerebral (IC), and/or intrathecal (IT) injections. In the following section, we discuss the different modalities of gene therapy in greater detail.Table 2 Overview of existing gene therapy clinical trials for primary leukodystrophies.

Table 2Trial ID	# Patients Enrolled	Intervention/Treatment	Targeted Patient Population	Phase	Start date - completion date	
Metachromatic leukodystrophy	
NCT01560182	20	IV HSC-directed LV gene therapy (arsa-cel)	Pre-sx or early sx LI or EJ MLD	Phase 1/2	2010–2025	
NCT03392987	10	IV HSC-directed LV gene therapy (arsa-cel)	Pre-sx or early sx LI or EJ MLD	Phase 2	2018–2028	
NCT04283227	6	IV HSC-directed LV gene therapy (arsa-cel)	Pre-sx or early sx LJ MLD	Phase 3	2022–2031	
NCT02559830	50	IV HSC-directed LV gene therapy	Age of symptom onset <16 yrs, non-end stage MLD	Phase 1/2	2015–2025	
NCT03725670	10	IC LV gene therapy	All MLD patients with abnormal bMRI	Not reported	2018–2020	
NCT01801709	5	IC AAV gene therapy (AAVrh.10cuARSA)	Early-onset MLD ages 6 mo to 5 yrs	Phase 1/2	2014–2029	
X-linked adrenoleukodystrophy	
NCT01896102	32	IV HSC-directed LV gene therapy (eli-cel)	Active CALD ages ≤17 yrs	Phase 2/3	2013–2021	
NCT03852498	35	IV HSC-directed LV gene therapy (eli-cel)	Active CALD ages ≤17 yrs	Phase 3	2019–2024	
NCT02698579	67	IV HSC-directed LV gene therapy (eli-cel)	Having received eli-cel in parent study	Long term follow-up	2016–2037	
NCT02559830	50	IV HSC-directed LV gene therapy	Age of symptom onset <16 yrs, non-end stage X-ALD	Phase 1/2	2015–2025	
NCT03727555	10	IC LV gene therapy	All symptomatic X-ALD patients, NFS≥1	Not reported	2018–2020	
NCT05394064	16	IT AAV9 gene therapy (SBT101)	All AMN patients able to ambulate	Phase 1/2	2022–2029	
Globoid cell leukodystrophy	
NCT04693598	6	IV CNS-directed AAVrh.10 gene therapy (FBX-101)	EI GLD patients, received allogeneic HSCT	Phase 1/2	2021–2024	
NCT05739643	12	IV CNS-directed AAVrh.10 gene therapy (FBX-101)	Infantile GLD patients, received allogeneic HSCT	Phase 1/2	2023–2025	
NCT06308718	25	IV CNS-directed AAVrh.10 gene therapy (FBX-101)	All patients who received FBX-101	Long term follow-up	2024–2029	
NCT04771416	24	ICM AAV.Hu68 gene therapy (PBKR03)	EI GLD patients ages 1–9 mo old	Phase 1/2	2022–2030	
Canavan disease	
NCT04833907	24	ICV AAV gene therapy (rAAV-Olig001-ASPA)	CD patients ≤60 mo old	Phase 1/2	2021–2024	
NCT04998396	18	IV AAV9 gene therapy (BBP-812)	CD patients ≤30 mo old	Phase 1/2	2021–2028	
NCT05317780	1	IV and ICV dual-route AAV gene therapy (AAV9-CB6-ASPA)	Single 6-mo-old male CD patient	Single-patient investigational new drug	2022- N/A	
Giant axonal neuropathy	
NCT02362438	21	IT AAV9 gene therapy (scAAV9/JeT-GAN)	GAN patients ≥3 years old	Phase 1	2015–2030	
GM2 gangliosidoses	
NCT04669535	11	Intrathalamic and ICM gene therapy (AXO-AAV-GM2)	TSD or SD patients between 6 mo and 12 yrs old	Phase 1	2021–2024	
Alexander disease	
NCT04849741	73	IT ASO (ION373)	AxD patients between 2 and 65 years old	Phase 1/2/3	2021–2025	
Pelizaeus-Merzbacher disease	
NCT06150716	24	IT ASO (ION356)	Male PMD patients between 2 and 17 yrs old	Phase 1b	2023–2028	
Abbreviations: ASO: antisense oligonucleotides; AxD: Alexander disease; bMRI: brain magnetic resonance imaging; CALD: cerebral adrenoleukodystrophy; CNS: central nervous system; EI: early infantile; EJ: early juvenile; GAN: giant axonal neuropathy; GLD: globoid cell leukodystrophy; HSC: hematopoietic stem cell; IC: intracranial; ICM: intra-cisterna magna; ICV: intracerebroventricular; IT: intrathecal; IV: intravenous; LI: late infantile; LV: lentivirus; MLD: Metachromatic leukodytrophy; mo: months; PMD: Pelizaeus-Merzbacher disease; SD: Sandhoff disease; Sx: symptomatic; TSD: Tay-Sachs disease; X-ALD: X-linked adrenoleukodystophy; yrs: years.

Ex vivo hematopoietic stem cell-directed gene therapy

Ex vivo HSC-directed gene therapy provides gene replacement to peripherally mobilized HSCs, after which the corrected cells are returned to the patient through autologous hematopoietic stem cell transplantation (HSCT) (Fig. 3, left panel). Recombinant lentiviral (LV) vectors have undergone multiple generations of engineering to enhance safety and efficiency of HSC-directed gene delivery [11] and they are the viral vector of choice for ex vivo HSC-directed gene therapy.Fig. 3 Depiction of the different modalities of gene-based therapies currently in use for leukodystrophy clinical trials, including ex vivo LV-mediated gene therapies (left panel), in vivo AAV-mediated gene therapies (middle panel), and antisense oligonucleotide therapies (right panel). Abbreviations: X-ALD: X-linked adrenoleukodystrophy, MLD: Metachromatic leukodystrophy, GLD: Globoid cell leukodystrophy, CD: Canavan disease, GAN: Giant axonal neuropathy; TSD: Tay-Sachs disease; SD: Sandhoff disease; PMD: Pelizaeus-Merzbacher disease.

Fig. 3

Much of the data supporting HSC-directed ex vivo gene therapy derive from allogeneic HSCT in the forms of bone marrow transplantation and umbilical cord blood transplantation (UCBT). Over the last few decades, allogeneic HSCT has become the standard of care for many leukodystrophies [12], [13], [14], [15], [16], [17], [18], [19], [20], [22]. It effectively provides gene replacement in the CNS by engrafting donor-derived monocytes as healthy microglia-like cells in the CNS to correct pathologic neuroinflammation mediated by diseased microglia [23], [21]. This therapeutically targets CNS disease through the more easily accessible hematopoietic system. For leukodystrophies successfully treated with allogeneic HSCT, there is strong support for ex vivo HSC-directed gene therapy approaches even when animal disease models do not exist.

Unlike allogeneic HSCT, ex vivo LV-mediated gene therapy drives supraphysiologic gene expression in transduced autologous HSCs and their progeny. For some leukodystrophies, supraphysiologic gene expression can enhance the therapeutic efficacy of HSCT [24], but for others, supraphysiologic gene expression may have unforeseen cytotoxic effects that preclude its clinical use [25,26]. For leukodystrophies that fall into the former category, ex vivo HSC-directed gene therapy can replace allogeneic HSCT and eliminate two critical disadvantages inherent to allogeneic HSCT: the search for a compatible donor and the complications associated with chronic immunosuppression.

Although LV-mediated gene delivery is a powerful tool, there are important limitations and drawbacks to consider. The most important limitation is genomic integration of LV vectors [27]. While stable integration allows for long-term gene expression, integration-related insertional mutagenesis at cancer-associated loci can have significant oncogenic potential [28], especially at high transduction efficiencies that result in high vector copy number per transduced cell.

Another major limitation is the nine kilobase (kb) packaging size of LV vectors. Although this enables packaging of larger genes, it also limits diffusivity in the extracellular matrix and reduces CNS biodistribution with in vivo delivery. This is especially limiting in larger animal models and humans [29]. While some preclinical studies show increased CNS distribution with targeted LV envelope engineering [30], these vectors have not yet reached clinical trials. Thus, LVs are predominantly used for ex vivo delivery, enabling a cell-based gene therapy product for the leukodystrophies.

In vivo central nervous system-directed gene therapy

CNS-directed in vivo gene therapy targets primary CNS disorders by directly transducing neurons and other CNS cell types (Fig. 3, middle panel). The overwhelming majority of CNS-directed in vivo gene delivery is mediated by recombinant adeno-associated virus (AAV) vectors. AAV is a single-stranded DNA parvovirus with a diverse array of naturally occurring and engineered serotypes. By pairing the AAV2 genome with capsids from different serotypes, it is possible to greatly enhance CNS transduction by targeting neurons (AAV9 [[31], [32], [33], [34]], AAVrh.10 [35,36]) and oligodendrocytes (AAV-Olig001 [37], AAVhu68 [38]). Other important CNS-specific AAV capsid features include: 1) BBB penetrance, which allows less invasive IV delivery of CNS-targeted gene therapies [39,40]; 2) retrograde and anterograde axonal transport [41,42], which increases CNS transduction and targets leuko-axonopathies; and 3) non-human primate vector origin, which overcomes pre-existing human AAV immunity. Recombinant AAV serotypes specific to each clinical trial will be discussed in greater detail in the ensuing sections.

A major limitation of existing AAV capsids is their inability to transduce microglia efficiently. Although recent publications have made progress in microglial tropism [43], these technologies have not yet been approved for clinical use. Currently, HSC-directed gene therapy remains the most efficient way to target microgliopathies by allowing corrected monocyte-derived microglia to populate the CNS.

The promoter is another important factor to consider when designing AAV vectors for gene therapy. Some promoters induce supraphysiologic and ubiquitous transgene expression [44,45]. Others have lower expression levels but may have other desired features, such as smaller size, which facilitates accommodation of larger transgenes without exceeding the 4.7 ​kb AAV packaging limit [46].

Compared to LV vectors, AAV vectors are classically considered to be much safer gene delivery vehicles. Instead of integrating into the human genome, AAV mediates long-term gene expression mainly by persisting in episomal form [47], which at least in theory reduces the risk for genotoxicity. However, there are three primary disadvantages associated with AAV-mediated gene therapy: 1) the limited 4.7 ​kb AAV packaging capacity, 2) pre-existing anti-AAV antibody titers that have already excluded up to 20% of patients from receiving life-saving therapy [48], and 3) immunotoxicity associated with high dose AAV administration, which necessitates treatment with immunosuppressive medications [49].

Antisense oligonucleotides

Beyond viral vectors, antisense oligonucleotide (ASO) therapy is another form of gene therapy that is predominantly used to modify gene expression at the ribonucleic acid (RNA) level (Fig. 3, right panel). ASOs are synthetic, short, and single-stranded oligodeoxyribonucleotides or oligoribonucleotides that bind to transcribed mRNA via complementary “antisense” base pairing [50,51]. In doing so, ASOs alter pre-mRNA splicing, mRNA stability, mRNA translation, and RNA-protein interactions [[12], [13], [14]]. There are currently two ASOs in clinical trials for Alexander disease and Pelizaeus-Merzbacher disease, leukodystrophies with toxic gain-of-function mutations. ASOs targeting these disorders downregulate expression of the mutant proteins by suppressing mRNA expression.

Gene therapy clinical trials for leukodystrophies

Within the leukodystrophies, there are active gene therapy clinical trials for metachromatic leukodystrophy, adrenoleukodystrophy, globoid cell leukodystrophy, Canavan disease, giant axonal neuropathy, GM2 gangliosidoses, Alexander disease, and Pelizaeus-Merzbacher disease (Table 2). Here, we provide a brief overview of the pathophysiology and clinical features for each leukodystrophy. Then we present the seminal preclinical gene therapy studies and the existing clinical trials derived from these studies. Because many gene therapies share a similar profile of serious adverse events, we postpone discussion of adverse events to the next section.

Metachromatic leukodystrophy

Pathophysiology and clinical presentation

Metachromatic leukodystrophy (MLD) is an autosomal recessive lysosomal storage disorder that presents in patients who have a deficiency in arylsulfatase A (ARSA) activity. ARSA hydrolyzes sulfatides, and accumulation of sulfatides in MLD destabilizes myelin and impairs oligodendrocytes and Schwann cells, thereby causing a demyelinating leukodystrophy of the CNS and PNS [52,53].

MLD is clinically classified according to age at disease onset: late infantile onset (≤2.5 years), juvenile onset (2.5–16 years), and adult onset (≥16 years) variants [53]. Patients with higher residual enzyme activity are more likely to have milder disease while patients with no or minimal ARSA activity have more severe disease. Late-infantile MLD patients experience rapidly progressive clinical deterioration involving developmental regression, spastic quadriparesis, loss of fine motor control and communication, blindness, deafness, seizures, and death around five to eight years. Juvenile onset MLD initially manifests with psychiatric, cognitive, learning, and attentional problems, followed by spasticity and weakness related to upper motor neuron dysfunction. Patients often live for years in a vegetative state with supportive care. Adult-onset MLD initially presents with psychosis, depression, mood swings, and other neuropsychiatric abnormalities. Over many years, patients experience periods of relative disease stability followed by episodes of exacerbation involving loss of motor skills, bowel and bladder control, speech, and cognition. Death typically occurs 20–30 years after initial diagnosis.

Lentivirus-mediated HSC-directed gene therapy

Preclinical studies

The therapeutic success of allogeneic HSCT [24,54,55] prompted the first preclinical ex vivo HSC-directed LV-mediated gene therapy study [56] in an MLD mouse model that recapitulates the biochemical features of human MLD with some parallels in neuropathologic findings and a milder disease phenotype [57]. By transplanting syngeneic transduced donor MLD mouse HSCs into lethally irradiated MLD recipient mice, this seminal study provided proof-of-concept for the therapeutic viability of ex vivo HSC-directed gene therapy by showing: 1) sustained bone marrow engraftment of donor HSCs with supraphysiologic ARSA activity; 2) multilineage hematopoietic reconstitution with transgene-expressing progeny cells; 3) CNS and PNS engraftment of donor-derived cells; and 4) amelioration of the biochemical, neuropathologic, and clinicobehavioral features of murine MLD [56]. Interestingly, the degree of clinical efficacy for ex vivo LV-ARSA gene therapy appeared to be proportional to the degree of LV-mediated ARSA overexpression. A follow-up study showed that ARSA produced by donor monocyte-derived microglia-like cells could correct neighboring ARSA-deficient neurons and glia [58] through a physiologic lysosomal enzyme trafficking process known as cross-correction [59].

Clinical trials

Following two open-label, non-randomized phase 1/2 human clinical trials with expanded access for atidarsagene autotemcel (arsa-cel) (NCT01560182, NCT03392987), this approach received FDA approval in 2024. Arsa-cel is an ex vivo HSC-directed LV-mediated gene therapy for pre-symptomatic late-infantile, presymptomatic juvenile, and early symptomatic juvenile MLD patients. Interim data analysis at three years of median follow-up time showed biochemical disease correction with persistent supraphysiologic ARSA activity in peripheral blood mononuclear cells (PBMCs). Persistent physiologic ARSA activity in the cerebrospinal fluid (CSF) was indirect evidence for CNS engraftment of donor cells. Treated patients had significantly fewer demyelinating lesions on brain MRI compared to the natural history cohort. This was associated with improvements in gross motor function, increased event-free survival, and normalization or near-normalization of cognitive performance and verbal skills [[60], [61], [62]]. At a median follow-up of 6.76 years, 25/26 treated patients continued to have preserved ambulation [63]. In contrast, 50% of untreated late infantile MLD patients lose their ability to walk a year after symptom onset [64]. Arsa-cel is now being evaluated in a clinical trial for late-juvenile MLD patients (NCT04283227).

Despite these exciting data, not all MLD patients had positive outcomes in the clinical trials. Two early juvenile MLD patients with pre-existing mild cognitive or gait difficulties died shortly after gene therapy infusion due to rapid disease progression. This lends further support to previously published data in allogeneic HSCT suggesting that the presence of pre-treatment neurologic symptoms is a predictor of poor treatment outcomes [13,14,65]. The availability of a disease-modifying therapy will help implement newborn screening, which will in turn facilitate early diagnosis and gene therapy administration in the presymptomatic phase, thereby giving patients the best chance for maximal therapeutic effect.

The short follow-up period for arsa-cel limits its direct comparison to allogeneic HSCT outcomes. Published data suggest a trend toward improved survival, motor function, and cognitive function for patients receiving arsa-cel [12,13,24]. Autopsy studies for MLD patients who received allogeneic HSCT confirmed the presence of CNS donor monocyte-derived microglia-like cells and found evidence of remyelination despite a surprising lack of CNS cross correction [21,66]. Although there are no published autopsy data for MLD patients who received arsa-cel, the pre-clinical murine studies [56,58] suggest that CNS cross-correction is exclusively associated with LV-mediated supraphysiologic ARSA expression. Thus, transduced donor cell-mediated cross-correction of neuronal and glial cells may be responsible for the observed improved clinical outcomes of arsa-cel. Additional studies will be needed to test this hypothesis.

A similar ex vivo HSC-directed LV-mediated gene therapy is being conducted in China for all MLD patients with disease onset ≤16 years (NCT02559830). Unlike the clinical trials presented above, this clinical trial targets symptomatic MLD patients, and presymptomatic disease is an exclusion criterion. No published data are available for this trial.

LV-mediated CNS-directed gene therapy

LV-mediated gene therapies are limited by lack of widespread CNS biodistribution due to large viral particle size and resulting low diffusivity within the extracellular space. This limitation is less apparent in mice due to their small brain size. Intracerebral LV-ARSA prevented local hippocampal neuropathology in MLD mice, which corresponded to a small but significant reduction in learning impairment [67]. Since as little as 5% residual ARSA activity can prevent symptomatic MLD [68,69], there is a clinical trial in China studying CNS-directed LV-ARSA gene therapy for MLD patients (NCT03725670). However, no trial-related data have been published to date.

AAV-mediated CNS-directed gene therapy

One limitation of HSC-directed gene therapy is the inevitable delay between gene therapy infusion and CNS engraftment. This explains the observed 12- to 24-month delay between allogeneic HSCT and any measurable clinical therapeutic benefit [55]. This also explains why more advanced MLD patients derive no benefit from allogeneic HSCT. Direct IC gene therapy could facilitate rapid supraphysiologic transgene expression in the CNS and potentially arrest CNS demyelination without delay.

Preclinical studies

Following up on promising preclinical studies using the older generation AAV5 serotype [70,71], Piguet et al. directed a single AAVrh.10-ARSA injection targeting the right striatum in MLD mice, which resulted in widespread supraphysiologic ARSA activity in the ipsilateral hemisphere and low but detectable ARSA expression in the contralateral hemisphere [35]. While behavioral data for MLD mice treated with AAVrh.10-ARSA are lacking, treatment with AAV5-ARSA at the presymptomatic stage improved motor function [71]. Compared to AAV5, AAVrh.10 showed wider supratentorial transduction, increased transgene expression, and cross correction of neighboring oligodendrocytes [35]. This justified the translation of IC AAVrh.10-ARSA gene therapy to clinical trial.

Clinical studies

Despite the promising preclinical efficacy data in mice and the favorable biodistribution and biosafety data of the AAVrh.10-ARSA vector in nonhuman primates (NHPs) [72], an open-label, single-arm, monocentric phase 1/2 trial to evaluate the safety and efficacy of IC AAVrh.10-ARSA administration (NCT01801709) showed no clinical benefit for presymptomatic or early-symptomatic MLD patients [73].

The failure of this clinical trial is unexpected and unexplained. However, there are a few possible contributors to consider. Human brains have a volume of around 1400 ​cm3 [74], whereas adult mouse brains average around 2 ​cm3 [75]. The 700-fold difference in brain sizes may have resulted in inadequate viral transduction, CNS biodistribution, and cross correction of brain cells critical for disease modification. Follow up toxicity studies in NHPs identified parenchymal neuroinflammation with microglial activation and CNS infiltration of lymphocytes and monocyte-derived microglia-like cells at a dose of 1.3 ​× ​1011 viral genomes (vg) per injection site for both AAVrh.10-ARSA and empty (non-transgene-encoding) AAVrh.10 vectors [76]. The higher dose used in the clinical trial (3.3 ​× ​1011 vg/site) exceeds the toxic dose and the lower dose (8.3 ​× ​1010 vg/site) is higher than the identified maximal safe dose (2.4 ​× ​109 vg/site). In MLD pathophysiology, abnormal microglial activation precedes myelin destruction [77]. AAV-related neuroinflammation may further decompensate an intrinsically vulnerable microglial population and precipitate and/or accelerate MLD disease progression. This paradoxical AAV-mediated acceleration of pathologic microglial activation with associated lymphocytic infiltration has been previously reported in a different leukodystrophy mouse model with progressive disease-associated neuroinflammation [78].

X-linked adrenoleukodystrophy

Pathophysiology and clinical presentation

X-linked adrenoleukodystrophy (X-ALD) is a demyelinating peroxisomal disorder that classically presents in boys and men with hemizygous mutations in the ATP-binding cassette subfamily D member 1 (ABCD1) gene. ABCD1 encodes adrenoleukodystrophy protein (ALDP), a transporter for very long-chain fatty acids (VLCFAs) to the peroxisome where they undergo β-oxidation [79]. There are two neurologic phenotypes associated with X-ALD, cerebral ALD (CALD) and adrenomyeloneuropathy (AMN). CALD is a severe demyelinating phenotype in the brain that develops in 35% of X-ALD boys ≤10 years old. Boys with CALD present with visual and auditory processing difficulties, loss of communication, personality changes, spastic quadriparesis, tube feeding dependence, urinary and fecal incontinence, and seizures. Death typically occurs two to five years after symptom onset. AMN is the most common X-ALD phenotype characterized by an insidious progression of spinal cord and peripheral nerve demyelination. Patients with AMN present in their 20s–30s with progressive spastic paraparesis, sensory loss, neurogenic bladder, and sexual dysfunction. Around 45% of AMN patients eventually develop CALD [80,81].

How ABCD1 deficiency causes a demyelinating phenotype in CALD is poorly understood, although it is thought to involve a pathologic positive feedback loop driven by VLCFA accumulation, which damages tissue, increases oxidative stress, and promotes neuroinflammation [79]. Neuropathologic analysis of brain tissue from CALD patients shows evidence of a pathologic process initiated by microglial activation and apoptosis and ending with a confluent necrotic white matter lesion with no remaining oligodendrocytes, myelin, or axons [82].

Lentivirus-mediated HSC-directed gene therapy

Preclinical studies

There is no animal model of CALD, precluding preclinical studies of therapeutic efficacy. Instead, preclinical studies used human LV-ABCD1 transduced HSCs to show successful human HSC engraftment in the bone marrow [83] and CNS [84] of nonobese diabetic/severe combined immunodeficient recipient mice. These studies provided proof-of-concept for HSC-directed LV-ABCD1 gene therapy, directly enabling clinical trials. It is important to recognize that the lack of an animal CALD model did not hinder the clinical translation of this therapeutic approach to patients in need. Instead, clinical translation was supported by the success of allogeneic HSCT in the same disease context.

Clinical studies

Building on the therapeutic success of allogeneic HSCT [15,16,85,86], four CALD boys with no HLA-compatible HSC donors underwent the first ex vivo LV-ABCD1 gene therapy. These patients initially experienced clinical stabilization and discontinuation of active demyelination starting 14–16 months after gene therapy infusion, but three of the four patients eventually experienced severe neurologic decompensation in the setting of disease progression [87,88]. The eventual disease progression was attributed to low viral genome copies and low ALDP expression. Since then, there have been larger phase 2/3 and long-term follow-up clinical trials in the United States (NCT01896102, NCT03852498, NCT02698579), as well as a small phase 1 clinical trial in China (NCT02559830) to assess clinical efficacy and safety of LV-ABCD1 gene therapy. We review data derived from the US clinical trials as there are no published data available from the Chinese trial.

The US clinical trials for elivaldogene autotemcel (eli-cel) enrolled boys ≤17 years who presented with early symptomatic CALD, defined as radiologic Loes score 0.5 to nine [89] and clinical neurologic functional scale (NFS) score ≤1 [90]. Presymptomatic X-ALD boys were excluded as it is impossible to predict which patients will develop the CALD phenotype. Fifteen of the 17 patients included in the interim analysis were alive without major functional disabilities or clinical symptoms with a median follow-up time of 29.4 months. Twelve treated patients had stable MRI findings without progression and two had increasing Loes scores with relative preservation of the NFS score. The results of this initial interim analysis [91] were largely confirmed in a subsequent interim analysis with 32 treated CALD patients [92]. Despite the strong clinical and imaging evidence for disease stabilization and biochemical evidence for ABCD1 transgene expression at a level twice as high as the initial French clinical trial [88], there was no decrease in plasma VLCFA levels. This is consistent with the known lack of correlation between VLCFA levels and disease severity [93]. Further, it suggests that <25% median restoration of ALDP expression in monocytes and macrophages is not enough to reduce plasma VLCFAs, although it is enough to rescue CNS disease. Based on these data, treatment of a focal CNS lesion is not contingent on restoration of VLCFA levels in plasma.

Of the two patients who died in the study, one experienced rapid disease progression immediately after eli-cel administration, possibly due to advanced disease pre-infusion given the expected 12-month period of disease progression between eli-cel administration and disease stabilization. The other patient was withdrawn from the study due to disease progression on imaging, and he unfortunately succumbed to complications related to a second allogeneic HSCT that was deemed unrelated to eli-cel administration. We discuss insertional mutagenesis in the eli-cel gene therapy trial in detail in a subsequent section.

LV-mediated intracerebral-directed gene therapy

There is an ongoing Chinese clinical trial studying CNS-directed LV-mediated gene therapy for CALD patients (NCT03727555), although no trial-related data have been published to date. The same limitations for CNS-directed LV administration we previously discussed for MLD apply to CALD.

AAV-mediated intrathecal-directed gene therapy

AMN is the most common X-ALD phenotype and the myeloneuropathic component affects both men and women [94]. There is a large clinical need and no available treatments targeting AMN. Single dose IT delivery of AAV9-ABCD1 in the mouse model of AMN [31] results in widespread transduction of neurons, astrocytes, vascular endothelial cells, and some microglia in the spinal cord. Importantly, the dorsal root ganglion, a major contributor to the progression of sensory abnormalities afflicting patients with AMN [95], is transduced, although there is no reduction of VLCFA accumulation [31]. A subsequent study of AAV9-ABCD1 targeting the intracerebroventricular (ICV) CSF space showed correction of neuropathologic abnormalities and functional motor improvement in AMN mice [96]. Importantly, IT administration of AAV9 vectors transduced the spinal cord and several brain regions with high efficiency in NHPs [97], demonstrating clinical translatability.

Clinical studies

A phase 1/2 randomized, blinded, dose-escalation study of IT delivery of SBT101 (AAV9-ABCD1) is enrolling independently ambulating adult men between 18 and 65 years old who have clinical evidence of AMN (NCT05394064). Dose selection was informed by murine and NHP biodistribution studies that were translated to human patients based on relative volumes of CSF [98]. Intrathecal administration of AAV-mediated gene therapy could lower the risk for adverse events by requiring much lower doses of AAV (1.0 ​× ​1014 to 3.0 ​× ​1014 vg/person) compared to systemic IV administration (as high as 3.0 ​× ​1014 vg/kg [99]). There are no interim data for SBT101 published to date.

Globoid cell leukodystrophy

Pathophysiology and clinical presentation

Globoid cell leukodystrophy (GLD) is a demyelinating leukodystrophy that presents in patients with autosomal recessive mutations in the GALC gene. GALC encodes galactosylceramidase (GALC), the lysosomal enzyme that hydrolyzes the metabolite, galactosylsphingosine, also known as psychosine [100]. Psychosine forms as a cytotoxic byproduct of myelin synthesis and accumulates primarily in the lipid rafts of oligodendrocytes, where it alters oligodendrocyte membrane architecture [101] and induces apoptosis of oligodendrocytes and Schwann cells [102]. The subsequent breakdown of myelin triggers a neuroinflammatory response with microglial and astrocytic activation as well as CNS infiltration of peripheral monocytes. The accumulation of phagocytosed myelin debris in microglia leads to the formation of the pathognomonic giant nucleated “globoid cells.” Cytotoxic psychosine accumulation is directly responsible for the clinical manifestations of GLD, independent of GALC deficiency [103]. In recent years, various important subcellular processes, including autophagy [104], extracellular vesicular trafficking [105], and α-synuclein pathology [106,107] have been implicated in GLD pathophysiology.

GLD is clinically classified based on age of onset: early infantile (0–13 months), late infantile (13–36 months), juvenile (3–16 years), and adult (>16 years). Early infantile GLD presents with irritability, feeding difficulties, optic atrophy, severe spasticity, posturing, and seizures with rapid culmination in death. Late infantile patients develop abnormal gait and visual difficulties, followed by spastic quadriparesis, seizures, temperature instability, and intermittent apneas. On average, patients succumb six years after presentation. Juvenile GLD similarly affects multiple domains, but disease progression occurs more slowly. Adult-onset GLD presents with motor and sensory polyneuropathies, mood alterations, cognitive slowing, and neuropsychiatric manifestations in addition to spasticity, upper motor neuron pattern weakness, and scoliosis over time. The clinical course and prognosis for adults are highly variable [108]. Psychosine accumulation is toxic to peripheral nerves, and a demyelinating peripheral neuropathy is a common and early clinical finding in GLD patients of all ages [109]. Allogeneic HSCT is currently the standard of care but must be completed in the presymptomatic or early symptomatic stages of disease to be effective [19].

AAV-mediated intravenous gene therapy

Preclinical studies

Recombinant AAV capsids that cross the BBB like AAVrh.10 [110] enable IV delivery of CNS-targeted gene therapies. Although IV delivery is generally not as efficient at transducing the CNS as direct IC delivery, IV delivery does not require general anesthesia and is a much less invasive procedure. GLD mice treated with IV AAVrh.10-GALC had a modest lifespan extension with supraphysiologic levels of GALC activity in the CNS and PNS [111]. The limited therapeutic efficacy of gene therapy, previously reported for other multiple older generation AAV serotypes [[112], [113], [114]], is due at least in part, to persistent pathologic neuroinflammation in the CNS of GLD mice [78]. The presence of AAV exacerbates GLD-associated microglial activation and induces an AAV-targeted lymphocytic infiltration that significantly limits the therapeutic potential of AAV-mediated monotherapy. Interestingly, HSCT drastically reduces both disease-associated and AAV-related neuroinflammation [78,115], and together with gene therapy, produces a synergistic increase in GLD murine lifespan [114,116] that is significantly more than that achieved with AAV monotherapy even at a tenfold higher dose [117]. This synergy has been confirmed in a preclinical study of IV AAVrh.10-GALC and HSCT combination therapy for canine GLD [118].

Clinical studies

There are two phase 1/2 non-blinded and non-randomized dose escalation clinical trials for IV delivery of FBX101, an AAVrh.10-mediated gene therapy for GALC replacement, in GLD patients who have already had allogeneic HSCT in the form of UCBT. The initial study (NCT04693598) is enrolling early infantile GLD patients only, whereas the second study (NCT05739643) expands patient eligibility to include early and late infantile GLD patients. Interim analysis for the first two treated patients reported increased plasma and CSF GALC activity, improvements in gross motor function, and normalized white matter in treated GLD patients compared to healthy controls [119]. A follow up trial (NCT06308718) is underway to assess the long-term efficacy of FBX-101 over three years.

AAV-mediated intra-cisterna magna gene therapy

Preclinical data

The cisterna magna is the CSF-filled space dorsal to the medulla and caudal to the cerebellum. Single injection delivery of AAVhu68, an engineered AAV9-derived capsid, to the cisterna magna in NHPs increased CNS transduction of the brain and spinal cord compared to lumbar IT delivery [120]. Treatment of GLD dogs with intra-cisterna magna (ICM)-delivery of AAVhu68-GALC resulted in supraphysiologic GALC activity in the cerebellum and at least physiologic levels in other CNS areas. Treated GLD dogs had decreased neuroinflammation, minimal psychosine accumulation, preserved myelination, restoration of brainstem auditory evoked responses, and normalized nerve conduction velocities (NCVs) [38]. Abnormal NCVs are a pathologic manifestation of human GLD that remains uncorrected with allogeneic HSCT, resulting in progressive peripheral neuropathy with significant functional impairment [20,121]. Correction of this deficit would significantly improve quality of life for GLD patients.

Clinical studies

A phase 1/2 clinical trial for ICM delivery of AAVhu68-GALC gene therapy (NCT04771416) was initiated in February 2022. However, this clinical trial was halted by the sponsor in early 2023 due to changes in the company strategy. There are no published data associated with this clinical trial.

Canavan disease

Pathophysiology and clinical presentation

Canavan disease (CD) is an autosomal recessive leukodystrophy that presents in patients with biallelic mutations in the ASPA gene. ASPA encodes aspartylacylase (ASPA), which catalyzes the hydrolysis of N-acetylaspartic acid (NAA) to aspartate and acetate. Acetate is an important metabolite for myelin formation [122] and abnormal accumulation of NAA promotes oligodendrocyte cell death [123]. However, how this eventually causes myelin vacuolization and spongy degeneration of the brain remains unknown.

CD presents in the first six months of life with hypotonia, head lag, and macrocephaly. Over time, hypotonia evolves into spasticity and patients develop vision loss, seizures, sleep disturbances, irritability, startle response, tonic spasms, fevers of unknown origin, and feeding difficulties [124]. Without treatment, most patients die before age ten. For a small subset of patients, the phenotype is milder with some degree of intellectual impairment, and the disease progression is slower [125].

AAV-mediated intracerebroventricular gene therapy

Preclinical studies

Most AAV serotypes with CNS tropism primarily transduce neurons, albeit with varying efficiency. Since CD primarily affects oligodendrocytes, CNS-directed AAV-mediated gene therapy with primary neuronal transduction has limited clinical efficacy [126,127]. To target oligodendrocytes, a new AAV capsid with oligodendrocyte-specific tropism, AAV/Olig1, was engineered through capsid shuffling [128]. Although AAV/Olig1 has limited traversal of the BBB [128], direct ICV administration of AAV/Olig1-ASPA resulted in widespread preferential transduction of oligodendrocytes primarily in the subcortical white matter. This translated to improved motor function [129] in an ASPA-deficient murine model of CD [123]. Clinical translation of the AAV/Olig1 vector would be a major advance in treating myelinopathies.

Clinical studies

A phase 1/2 clinical trial is currently enrolling CD patients 3 months–60 months of age in an open-label sequential cohort study to assess the safety and efficacy of ICV-directed AAV/Olig1-ASPA gene therapy (NCT04833907). There are currently no published interim data analyses for this trial.

AAV-mediated intravenous gene therapy

Preclinical studies

IV delivery of AAV9-ASPA to CD mice restored 50% physiologic ASPA activity in the brain, confirming successful CNS transduction [110]. Fifty percent restoration of CNS ASPA activity is sufficient for therapeutic effect, as there is a dramatic 27-fold increase in median lifespan in IV AAV9-ASPA treated CD mice compared to untreated CD mice. Despite the lifespan prolongation, there is incomplete restoration of motor function. This is a common therapeutic limitation for gene therapies with multiple possible contributing explanations, including incomplete CNS transduction and/or biodistribution, inadequate cell-specific transduction, and nonphysiologic gene expression. Technologic improvements in gene delivery in the past 20 years have already made remarkable progress in addressing these limitations for CD [130] and other leukodystrophies, and many newer advancements are in preclinical development.

Clinical studies

A phase 1/2 clinical trial for BBP-812 is currently enrolling CD patients under 30 months of age in an open-label sequential cohort study to evaluate the safety and efficacy of IV AAV9-ASPA gene therapy (NCT04998396). Interim data for four treated patients showed robust NAA reductions in urine, CSF, and brain, with initial suggestions of clinical stabilization [131]. A follow-up open-label, expanded-access clinical trial (NCT05317780) enrolled one CD patient for dual route IV and ICV administration of AAV9-ASPA, with subsequent reduction in CSF NAA accumulation, increase in CNS remyelination, progress in neurodevelopment, and reversal of cortical blindness. Although it is difficult to draw conclusions from an n ​= ​1 study, these data provide hope for future dual route gene therapy delivery modalities.

Giant axonal neuropathy

Pathophysiology and clinical presentation

Giant axonal neuropathy (GAN) is an autosomal recessive leuko-axonopathy that affects patients with mutations in the GAN gene. GAN encodes the gigaxonin protein [132], which is a subunit of E3 ubiquitin ligase that regulates intermediate filament (IF) turnover [133]. Loss-of-function GAN mutations result in pathologic IF aggregation in neuronal axons of the CNS and PNS.

Affected patients classically present in infancy or early childhood with distal-predominant sensorimotor peripheral axonal neuropathy and proximal motor weakness. CNS manifestations include developmental delay, cerebellar and pyramidal signs, cranial nerve abnormalities, and seizures [[134], [135], [136]]. Non-neurologic manifestations include kinky hair and long eyelashes [135], precocious puberty [137], skin abnormalities [138,139], gastrointestinal problems [140,141], diabetes [142], and renal tubular acidosis [138]. Most patients succumb to the disease in the third decade in the setting of respiratory failure [143]. A subset of patients with milder GAN phenotypes do not have CNS manifestations or kinky hair [144].

AAV-mediated intrathecal gene therapy

Preclinical studies

Several in vitro preclinical studies have demonstrated significant reductions in IF aggregation in GAN patient-derived fibroblasts [34,145,146] and induced pluripotent stem cell-derived motor neurons [147] after treatment with gene replacement therapy. These data precipitated preclinical studies in two different GAN mouse models [148,149]. ICM administration of AAV9-GAN leads to efficient CNS transduction with supraphysiologic GAN expression. This correlated with near complete, 50%, and 66% clearance of IF aggregation in the striatum, cortex, and dorsal root ganglia, respectively. Treated GAN mice showed a modest but significant improvement in motor function [34]. The observed magnitude of behavioral improvement may have been limited by the very modest deficits in untreated GAN mice [148].

Transgenic GAN expression was driven, not by the commonly used CAG promoter, but by the short JeT promoter to permit packaging of the entire GAN coding sequence into the AAV vector. JeT mediates transgene expression at 25% of CAG-mediated transgene expression levels [46], which is acceptable given low physiologic GAN expression under healthy conditions [150]. This is a useful strategy for gene replacement of other similarly large genes with low physiologic expression.

Clinical studies

A phase 1 open-label non-randomized IT dose escalation study for AAV9-GAN has enrolled 14 patients with a median follow-up time of 68.7 months (range 8.6–90.5 months) [151]. Four doses of AAV9-GAN were administered in this dose escalation study. Patients receiving the lowest dose did not experience any significant improvement in sensorimotor neuropathy, but patients receiving the three higher doses showed significant improvements in motor function and/or neuropathy severity scores. There was evidence of increased sensory nerve action potential amplitudes across the median and ulnar nerves, which persisted for 6–24 months, indicating successful reversal of sensory neuropathy. Interestingly, the degree of improvement did not correlate with escalating doses. Possible explanations include: 1) the treatment groups were not large enough to detect significant differences, 2) there is a maximum viral dose above which therapeutic efficacy plateaus or diminishes, and/or 3) clinical efficacy of viral-mediated gene delivery correlates not with gene dosage but with other factors such as area of CNS distribution or primary targeted cell type. Additional studies will need to be done to test these hypotheses.

GM2 gangliosidoses

Pathophysiology and clinical presentation

GM2 gangliosidoses are a group of leuko-axonopathies characterized by deficient degradation of GM2 gangliosides. Affected patients have mutations in the subunits of N-acetyl-β-hexosaminidase (Hex) isoenzymes or in their cofactor, GM2 activator protein. We focus on isoenzyme deficiencies in this review, as they are the targets for current gene therapy approaches. Biallelic mutations in HEXA, which encodes the α subunit, cause Tay-Sachs disease (TSD); biallelic mutations in HEXB, which encodes the β subunit, cause Sandhoff disease (SD) [152]. Toxic accumulation of GM2 gangliosides primarily occurs in neurons and triggers neuronal apoptosis [153,154] through calcium dyshomeostasis in the endoplasmic reticulum [155]. The mechanisms by which neuronal cell death drive myelin deficiency and hypomyelination remain unknown but are likely related to non-cell autonomous effects of the oligodendrocyte-axon unit.

Clinically, GM2 gangliosidoses are classified based on age of onset. Patients with the acute infantile variant have the most severe clinical course, presenting at three to six months of age with acute neurologic deterioration characterized by weakness, hypotonia, hyperreflexia, developmental regression, vision impairment, exaggerated startle response, seizures, and death before five years of age. Most patients have a cherry red macula on fundoscopic exam [156,157]. The subacute juvenile variant presents with developmental regression at two to five years old, followed by spasticity, loss of ambulation, loss of speech, seizures, and progressive brain atrophy, resulting in death by mid-adolescence [158]. Patients with the late-onset variant present in their teenage years or young adulthood. In addition to gait dysfunction and dysarthria, these patients develop neuropsychiatric manifestations and peripheral neuropathy [159]. Patients with SD but not TSD also have systemic disease manifestations, including hepatosplenomegaly, cardiomegaly, macroglossia, and skeletal abnormalities [152].

AAV-mediated intrathalamic gene therapy

Preclinical studies

Because Hex subunits α and β dimerize, simultaneous co-expression of both α and β subunits in a stoichiometrically balanced ratio is necessary for optimal production of recombinant Hex in gene replacement approaches for TSD and SD [[160], [161], [162]]. Experimental gene therapies for TSD and SD are studied using the murine SD model, which has a severe phenotype that more accurately mimics the human disease course than the murine TSD model [163,164]. A single hemispheric striatal injection of AAV-HEXA/AAV-HEXB significantly extended lifespan from four months to over six months [165] in SD mice. However, these mice developed severe unilateral motor deficits due to insufficient correction of the untreated hemisphere. In contrast, bilateral striatal injections extended the median lifespan to >400 days in SD mice, and dual route striatal and cerebellar injections nearly normalized median lifespan to ∼700 days [166]. These data provided proof-of-concept to advance this therapeutic strategy to clinical trials.

Widespread CNS-directed delivery of AAV-mediated gene therapy to large animals remains a challenge due to larger brain sizes. The thalamus is the relay station of the brain, and thalamic targeting of gene therapy increases CNS biodistribution through anterograde [167] and retrograde [168] axonal transport. In the feline SD model, bilateral thalamic AAV1-mediated gene therapy significantly extended feline lifespan and improved gait [169]. However, treated cats mounted an AAV-directed humoral response against the AAV1 capsid. To evade pre-existing antibodies, the HEXA and HEXB transgenes were packaged into the neurotropic AAVrh.8 capsid [169,170]. AAVrh.8-mediated gene therapy targeting the bilateral thalami and deep cerebellar nuclei effectively corrected biochemical abnormalities, prevented demyelinating lesions, and improved clinical function in SD cats [169,171,172]. Further, bi-thalamic AAVrh.8-mediated gene therapy in a sheep model of TSD [173,174] was comparably effective [175,176].

Clinical studies

There is an ongoing phase 1 AAVrh.8-mediated clinical trial for patients with TSD and SD between six months and 12 years of age (NCT04669535). Patients receive equimolar AAVrh.8-HEXA and AAVrh.8-HEXB gene therapy (AXO-AAV-GM2) delivered to the bilateral thalami and intrathecally. IT dosing is divided into ICM and thoracolumbar injections. We review published data from the first two treated TSD patients [177]. The first patient (TSD-001) presented with infantile-onset TSD at five to six months and received AXO-AAV-GM2 at 2.5 years old. Due to disease-related destruction of the thalami, this patient did not receive intrathalamic AAV, but instead received IT gene therapy only. This patient had significantly impaired neurologic function with a CHOP-INTEND score of 20 prior to treatment, which remained stable without further deterioration 2.5 years after receiving gene therapy.

The second patient (TSD-002) was presymptomatically diagnosed with TSD and had developed lower extremity weakness and a macular cherry red spot when enrolled at six months of age. This patient was treated at seven months of age with bilateral intrathalamic and divided IT AXO-AAV-GM2. TSD-002 had minimal neurologic deficits prior to treatment with a normal CHOP-INTEND score of 60. She experienced temporary disease stabilization with continued CNS myelination on brain MRI before experiencing disease progression starting six months after treatment. She eventually lost the ability to sit or respond to audiovisual stimuli, and she developed new seizures by 24 months of age.

For most leukodystrophies, treatment earlier in the disease course is generally associated with improved outcomes, but the two TSD patients published in this study do not follow this pattern. Moreover, the significant disease progression in TSD-002, who received gene therapy immediately after symptom onset, occurred despite the additional intrathalamic gene therapy this patient received. The additional dose lowered post-gene therapy GM2 ganglioside accumulation in the CSF. Correction of CSF and serum HexA activity was minimal, with <1% physiologic HexA activity in the serum and CSF for both patients, despite intrathecal AAV administration. Although this is a case series with two patients, the results raise some concerns about the sustained therapeutic efficacy of intrathalamic AAV administration for TSD and SD. Additional data will be needed before any clinically meaningful conclusions can be drawn.

Alexander disease

Pathophysiology and clinical presentation

Alexander disease (AxD) is an autosomal dominant astrocytopathy that presents in patients with monoallelic mutations in the GFAP gene. GFAP encodes glial fibrillary acidic protein (GFAP), the major IF in astrocytes. Mutant GFAP accumulation in astrocytes induces formation of Rosenthal fibers (RFs) [178,179] and alters GFAP metabolism [180]. There is associated astrocyte activation [181], proteosome dysfunction [182], impaired stress response [183], microglial activation [184], lymphocytic infiltration [181], and cellular apoptosis [185,186]. The exact mechanisms by which these pathologic processes induce cytotoxicity and demyelination have not been fully elucidated.

There are two subtypes of AxD that are differentiated by brain imaging features and age of onset. Type I AxD is a rapidly progressive and early-onset phenotype, characterized by a frontal-predominant demyelinating leukodystrophy on imaging. Patients present with motor and cognitive delays, seizures, megalencephaly, and paroxysmal deterioration. Type II AxD is characterized by atrophic white matter disease of the brainstem, cerebellum, and spinal cord. It is an insidiously progressive phenotype that can present at any age with upper motor neuron signs, autonomic features, and ataxia manifesting as bulbar symptoms, palatal clonus, and extraocular movement abnormalities. Later onset phenotypes progress more slowly and patients with adult-onset AxD can survive for >30 years after diagnosis [187,188].

Antisense oligonucleotide intrathecal gene therapy

Preclinical studies

ASOs treat gain-of-function GFAP mutations by suppressing expression of the mutant protein [189]. ICV administration of GFAP-targeting ASOs in two rodent AxD models reduced mutant GFAP accumulation and reversed neuropathology [190,191]. In the AxD rat model, which develops a robust clinical phenotype, presymptomatic ASO administration prevented motor abnormalities, and ASO administration five weeks after symptom onset incompletely reversed motor abnormalities. This is the first leukodystrophy gene therapy showing reversal of disease progression after symptom onset [182].

Clinical studies

A randomized, double-blind, parallel-assignment phase 1/2/3 clinical trial for IT zilganersen, a GFAP-targeting ASO, is enrolling AxD patients between two and 65 years old (NCT04849741). There is also an open-label sub-study for AxD patients under two years old. Like other CNS-targeted ASO clinical trials, the success of this trial will likely depend on the efficiency of cell-specific GFAP knockdown and the biodistribution of zilganersen in the human brain [192]. There are no published interim analyses.

Pelizaeus-Merzbacher disease

Pathophysiology and clinical presentation

Pelizaeus-Merzbacher disease (PMD) is a hypomyelinating leukodystrophy presenting in patients with X-linked mutations in the PLP1 gene. PLP1 encodes myelin proteolipid protein (PLP) and DM20 through an alternative PLP1 splice product. Together, PLP and DM20 comprise 60–80% of the total protein content in myelin [193]. The pathophysiology of PLP1 mutations is heterogeneous due to the different types of pathogenic mutations. Toxic gain-of-function PLP1 mutations include gene duplications and mutations that disrupt protein folding. The resulting pathologic protein accumulation in the endoplasmic reticulum (ER) activates the ER stress response [194] and overwhelms the unfolded protein response [195], triggering oligodendrocyte apoptosis [196]. This results in the classic PMD clinical constellation of nystagmus, ataxia, dystonia, spastic paraplegia, and cognitive delay. Death occurs in the teenage years in the severe connatal form, but most patients with classic PMD survive into adulthood [197].

Alternatively, patients with PLP1 null mutations do not have nystagmus but present with a mild hereditary spastic quadriplegia (HSP). More conserved amino acid substitutions in PLP1 are associated with pure HSP, while less conserved mutations are associated with HSP with CNS hypomyelination.

Antisense oligonucleotide intrathecal gene therapy

Preclinical studies

PLP1 duplications occur in 70% of PMD patients [198], and ASO-mediated reduction of PLP1 expression to physiologic levels would, in theory, be curative. Further, the mild phenotype associated with PLP1 null mutations implies a wide therapeutic window for titration of PLP1 expression. ICV delivery of a PLP1-targeted ASO in a faithful mouse model of PMD [[199], [200], [201]] partially corrected biochemical, neuropathologic and behavioral deficits [202]. Of note, the incomplete correction of nerve conduction velocity in ASO-treated mice may parallel the peripheral neuropathy phenotype seen in patients with PLP1 null mutations. Although treated mice continue to experience some limitations in motor function, the 11-fold increase in lifespan demonstrates the clear efficacy of this therapeutic approach. Near-normalization of exploratory behaviors also suggests a significant improvement in quality of life.

Clinical studies

An interventional trial to assess the safety, pharmacokinetics, and pharmacodynamics of IT ION356, an ASO targeting PLP1, is currently enrolling male PMD patients between two and 17 years old with a PLP1 duplication (NCT06150716). There are no interim data published for this clinical trial.

Adverse events

Gene-based therapies have tremendous potential in changing the lives of leukodystrophy patients. However, clinical efficacy must be assessed in the context of therapy-related adverse events. Serious adverse events (SAEs) specific to gene-based therapies most commonly arise from genotoxicity and/or immuntoxicity. In this section, we discuss the pathophysiology and treatment for these SAEs.

Genotoxicity

Recombinant lentivirus

Recombinant lentiviruses derive from retroviruses that randomly integrate into the host genome. In the early 2000s, the FDA halted HSC-directed gene replacement therapy for severe combined immunodeficiency due to T cell leukemias that developed in six patients with retroviral vector integration near proto-oncogenes [[203], [204], [205]]. Although LVs are much safer than retroviruses, long-term transgene expression is reliant on LV integration so insertional mutagenesis and oncogenesis remain risks.

As of spring 2024, seven cases of myelodysplastic syndrome or acute myelogenous leukemia have been reported among more than 70 boys with childhood CALD treated with eli-cel to date [28,206]. Two patients had LV insertion at the MECOM locus, a known susceptibility locus for myeloid malignancies [207,208] and an inhibitor of cell cycle progression and differentiation of HSCs [209]. However, not all patients with MECOM locus integrations have developed therapy-related myeloid neoplasms (tMN), suggesting that there are likely additional oncogenic factors at play that have yet to be identified.

Preclinical safety data in animal models failed to identify the MECOM locus as a common integration site (CIS) in mice treated with LV gene therapy. Further, there was no increased fitness for clones with identified CISs after xenotransplantation into humanized Rag2−/−Il2rg−/− (Ragγ) mice [210]. These studies were likely limited by poor reconstitution of the myeloid lineage in Ragγ mice [211], which limits assessment of oncogenic potential in myeloid precursor cells. Mutations in oncogenic genes with a variant allele frequency (VAF) as low as 0.5% can give rise to tMNs [212]. The clonal evolution and expansion of a myeloid subclone at such low VAFs take time and may account for the observed one-to two-year latency in tMN diagnosis after LV gene therapy. The short 12-week interval between HSCT and LV integration analysis in the murine preclinical study was likely insufficient to assess for oncogenic potential. Thus, close long-term monitoring of CALD patients after LV gene therapy is critical.

Interestingly, there have been no cases of tMN in MLD patients who received arsa-cel. There are significant differences in the LV constructs between the two clinical trials, and additional studies are needed to determine how differences in LV constructs, transgenes, HSCT preconditioning regimens, and other factors may impact the oncogenic potential of LV-mediated gene therapy.

Recombinant AAV

Recombinant AAV is classically known as a nonintegrating virus that maintains long-term transgene expression by persisting in cells in episomal form [213,214]. However, AAV genome integration does occur, albeit at a much lower rate, in mice [215,216], dogs [217], primates [218], and humans [219,220]. Integration in the murine genome at the Rian locus induces hepatocellular carcinoma (HCC) in mice [221,222]. Although the murine Rian locus is partially syntenic to the human Rian locus, no AAV integrations in the human Rian locus have been identified to date. Further, there are no reports of human malignancies associated with AAV integration except one case of HCC in a hemophilia B patient who was then found to have multiple other coexisting risk factors for HCC [223]. Given the relatively short follow-up time so far for most AAV clinical trials however, it is imperative to continue close long-term monitoring of all patients receiving AAV-mediated gene therapy.

Immunotoxicity

Recombinant lentivirus

Immunotoxic adverse events are triggered by immune activation against the recombinant virus or the encoded transgene, both of which can be identified as foreign by the patient’s native immune system. Ex vivo delivery of LV to HSCs is a widely used delivery strategy that minimizes immune responses and immunotoxic adverse events. The arsa-cel MLD clinical trials reported six events of low-titer transient antibodies against the ARSA transgene product with no impact on pharmacodynamics or clinical outcomes [62]. There have been no published reports of antibodies against the ABCD1 transgene product in the eli-cel clinical trial [91], although continued monitoring will be very important.

Recombinant AAV

Although AAV is classically known as a virus with low immunogenicity, immunotoxicity is a concern for patients receiving high dose AAV-mediated gene therapy. Thrombotic microangiopathy (TMA) is an SAE that develops in the setting of an immunotoxic response to very high doses of AAV >1014 vg/kg. Many IV AAV-mediated gene therapies in clinical trials are in this high dose range [[224], [225], [226]].

TMA is an endothelial injury syndrome characterized by profound thrombocytopenia due to hepatic platelet sequestration [227] and acute liver injury of varying degrees of severity. The kidneys, pancreas, skin, and heart can also be affected [228]. The pathophysiology of TMA is not fully understood, but the complement system [229] is a primary mediator of the immunotoxic response. Recombinant AAV activates the classical [230] and alternative [231] complement pathways, which induce liver sinusoidal endothelial injury, formation of platelet microthrombi, and hepatic platelet sequestration [227].

Due to the immunotoxic SAEs associated with high dose AAV administration, all patients who receive AAV routinely receive steroids for immunosuppression to prevent acute liver injury. However, steroids alone do not prevent thrombocytopenia, complement activation, or antibody formation [49]. Eculizumab, a monoclonal antibody against C5, has successfully blocked the immunotoxic response associated with TMA [232]. However, these studies were done for HSCT-associated TMA. Additional studies will need to be done to assess therapeutic efficacy in the context of AAV-associated TMA.

Future directions

Over the last 20 years, gene therapies for leukodystrophies have advanced beyond the preclinical realm and reached the clinical setting. For many, the availability of these therapies is life changing. The field continues to advance rapidly in the development of newer gene therapy delivery technologies that creatively evade SAEs while maximizing the potential to achieve a functional genetic “cure.” Areas that are being actively researched include but are not limited to: 1) increasing CNS transduction and biodistribution with bioengineered viral capsids [233]; 2) improving CNS cell-specific targeting to microglia [[234], [235], [236]] to treat primary and secondary microglial pathologies shared by many leukodystrophies; 3) liver-detargeted capsids to minimize hepatotoxicity [237,238]; 4) immune system evasion to expand treatment access to patients who have pre-existing antibodies against viral vectors [239,240]; etc. Further, the recent advent of precision genome editing enables targeted editing of the native genomic DNA, which maintains physiologic expression of corrected gene products and avoids cytotoxic adverse events related to nonphysiologic gene dosing [241]. Although each of these advances will need to be extensively evaluated for safety and efficacy prior to clinical translation, continued improvement in clinical outcomes is now the reality for many leukodystrophies that were once considered universally fatal and untreatable. Despite the progress, vulnerability in the leukodystrophy population demands increased attention. Adverse events specific to distinct classes of gene therapy are increasingly recognized, and the impact of disease-specific pathophysiology brings further unknowns. Ultimately, therapeutic benefits and risks will need to be evaluated in a disease-specific context.

Author contributions

Jasna Metovic and Yedda Li performed the literature review and wrote the first draft of the manuscript. Yi Gong edited and provided comments and revisions. Florian Eichler supervised the review and revised and edited the manuscript.

Declaration of competing interest

F.S. Eichler receives research support from NINDS (R01NS072446, R01NS082331, U54NS115052), institutional contracts from ASPA Therapeutics, Sanofi, Ionis, bluebird bio and Minoryx Therapeutics, and performs personal consulting for Sanofi, ASPA Therapeutics, UpToDate, Leal, Takeda, Atlas Venture, Acadia Pharmaceuticals and SwanBio Therapeutics.
==== Refs
References

1 Bonkowsky J.L. Nelson C. Kingston J.L. Filloux F.M. Mundorff M.B. Srivastava R. The burden of inherited leukodystrophies in children(e–Pub ahead of print)(CME) Neurology 75 2010 718 725 10.1212/WNL.0b013e3181eee46b 20660364
2 van der Knaap M.S. Bugiani M. Leukodystrophies: a proposed classification system based on pathological changes and pathogenetic mechanisms Acta Neuropathol 134 2017 351 382 10.1007/s00401-017-1739-1 28638987
3 Nowacki J.C. Fields A.M. Fu M.M. Emerging cellular themes in leukodystrophies Front Cell Dev Biol 10 2022 10.3389/fcell.2022.902261
4 Aerts-Kaya F. van Til N.P. Gene and cellular therapies for leukodystrophies Pharmaceutics 15 2023 2522 10.3390/pharmaceutics15112522 38004502
5 van der Knaap M.S. Schiffmann R. Mochel F. Wolf N.I. Diagnosis, prognosis, and treatment of leukodystrophies Lancet Neurol 18 2019 962 972 10.1016/S1474-4422(19)30143-7 31307818
6 Muthusamy K. Sivadasan A. Dixon L. Sudhakar S. Thomas M. Danda S. Adult-onset leukodystrophies: a practical guide, recent treatment updates, and future directions Front Neurol 14 2023 1219324 10.3389/fneur.2023.1219324
7 Zarekiani P. Nogueira Pinto H. Hol E.M. Bugiani M. de Vries H.E. The neurovascular unit in leukodystrophies: towards solving the puzzle Fluids Barriers CNS 19 2022 18 10.1186/s12987-022-00316-0 35227276
8 Archie S.R. Al Shoyaib A. Cucullo L. Blood-brain barrier dysfunction in CNS disorders and putative therapeutic targets: an overview Pharmaceutics 13 2021 1779 10.3390/pharmaceutics13111779 34834200
9 Gowing G. Svendsen S. Svendsen C.N. Chapter 4 - ex vivo gene therapy for the treatment of neurological disorders Dunnett S.B. Björklund A. Progress in brain research vol. 230 2017 Elsevier 99 132 10.1016/bs.pbr.2016.11.003
10 Brenner D. Ludolph A.C. Weishaupt J.H. Gene specific therapies – the next therapeutic milestone in neurology Neurol Res Pract 2 2020 25 10.1186/s42466-020-00075-z 33324928
11 Milone M.C. O'Doherty U. Clinical use of lentiviral vectors Leukemia 32 2018 1529 1541 10.1038/s41375-018-0106-0 29654266
12 Boucher A.A. Miller W. Shanley R. Ziegler R. Lund T. Raymond G. Long-term outcomes after allogeneic hematopoietic stem cell transplantation for metachromatic leukodystrophy: the largest single-institution cohort report Orphanet J Rare Dis 10 2015 94 10.1186/s13023-015-0313-y 26245762
13 Martin H.R. Poe M.D. Provenzale J.M. Kurtzberg J. Mendizabal A. Escolar M.L. Neurodevelopmental outcomes of umbilical cord blood transplantation in metachromatic leukodystrophy Biol Blood Marrow Transplant 19 2013 616 624 10.1016/j.bbmt.2013.01.010 23348427
14 van den Broek B.T.A. Page K. Paviglianiti A. Hol J. Allewelt H. Volt F. Early and late outcomes after cord blood transplantation for pediatric patients with inherited leukodystrophies Blood Adv 2 2018 49 60 10.1182/bloodadvances.2017010645 29344584
15 Shapiro E. Krivit W. Lockman L. Jambaqué I. Peters C. Cowan M. Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy Lancet 356 2000 713 718 10.1016/S0140-6736(00)02629-5 11085690
16 Peters C. Charnas L.R. Tan Y. Ziegler R.S. Shapiro E.G. DeFor T. Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999 Blood 104 2004 881 888 10.1182/blood-2003-10-3402 15073029
17 Matsukawa T. Yamamoto T. Honda A. Toya T. Ishiura H. Mitsui J. Clinical efficacy of haematopoietic stem cell transplantation for adult adrenoleukodystrophy Brain Commun 2 2020 fcz048 10.1093/braincomms/fcz048 32954314
18 Escolar M.L. Poe M.D. Provenzale J.M. Richards K.C. Allison J. Wood S. Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease N Engl J Med 352 2005 2069 2081 10.1056/NEJMoa042604 15901860
19 Yoon I.C. Bascou N.A. Poe M.D. Szabolcs P. Escolar M.L. Long-term neurodevelopmental outcomes of hematopoietic stem cell transplantation for late-infantile Krabbe disease Blood 137 2021 1719 1730 10.1182/blood.2020005477 33150395
20 Wright M.D. Poe M.D. DeRenzo A. Haldal S. Escolar M.L. Developmental outcomes of cord blood transplantation for Krabbe disease: a 15-year study Neurology 89 2017 1365 1372 10.1212/WNL.0000000000004418 28855403
21 Musolino P.L. Lund T.C. Pan J. Escolar M.L. Paker A.M. Duncan C.N. Hematopoietic stem cell transplantation in the leukodystrophies: a systematic review of the literature Neuropediatrics 45 2014 169 174 10.1055/s-0033-1364179 24459069
22 Wolf N.I. Breur M. Plug B. Beerepoot S. Westerveld A.S.R. van Rappard D.F. Metachromatic leukodystrophy and transplantation: remyelination, no cross-correction Ann Clin Transl Neurol 7 2020 169 180 10.1002/acn3.50975 31967741
23 de Vasconcelos P. Lacerda J.F. Hematopoietic stem cell transplantation for neurological disorders: a focus on inborn errors of metabolism Front Cell Neurosci 16 2022 895511 10.3389/fncel.2022.895511
24 Armstrong N. Olaye A. Noake C. Pang F. A systematic review of clinical effectiveness and safety for historical and current treatment options for metachromatic leukodystrophy in children, including atidarsagene autotemcel Orphanet J Rare Dis 18 2023 248 10.1186/s13023-023-02814-2 37644601
25 Visigalli I. Ungari S. Martino S. Park H. Cesani M. Gentner B. The galactocerebrosidase enzyme contributes to the maintenance of a functional hematopoietic stem cell niche Blood 116 2010 1857 1866 10.1182/blood-2009-12-256461 20511539
26 Gentner B. Visigalli I. Hiramatsu H. Lechman E. Ungari S. Giustacchini A. Identification of hematopoietic stem cell-specific miRNAs enables gene therapy of globoid cell leukodystrophy Sci Transl Med 2 2010 58ra84 10.1126/scitranslmed.3001522
27 Poletti V. Mavilio F. Designing lentiviral vectors for gene therapy of genetic diseases Viruses 13 2021 1526 10.3390/v13081526 34452394
28 Williams DA Bledsoe JR Duncan CN Eichler FS Grzywacz B Gupta AO Myelodysplastic syndromes after Eli-cel gene therapy for cerebral adrenoleukodystrophy (CALD) [ASGCT abstract 11] Mol Ther 30 2022 5S1
29 Kordower J.H. Bloch J. Ma S.Y. Chu Y. Palfi S. Roitberg B.Z. Lentiviral gene transfer to the nonhuman primate brain Exp Neurol 160 1999 1 16 10.1006/exnr.1999.7178 10630186
30 Humbel M. Ramosaj M. Zimmer V. Regio S. Aeby L. Moser S. Maximizing lentiviral vector gene transfer in the CNS Gene Ther 28 2021 75 88 10.1038/s41434-020-0172-6 32632267
31 Gong Y. Berenson A. Laheji F. Gao G. Wang D. Ng C. Intrathecal adeno-associated viral vector-mediated gene delivery for adrenomyeloneuropathy Hum Gene Ther 30 2019 544 555 10.1089/hum.2018.079 30358470
32 Corti M. Byrne B.J. Gessler D.J. Thompson G. Norman S. Lammers J. Adeno-associated virus-mediated gene therapy in a patient with Canavan disease using dual routes of administration and immune modulation Mol Ther Methods Clin Dev 30 2023 303 314 10.1016/j.omtm.2023.06.001 37601414
33 Ahmed S.S. Li H. Cao C. Sikoglu E.M. Denninger A.R. Su Q. A single intravenous rAAV injection as late as P20 achieves efficacious and sustained CNS Gene therapy in Canavan mice Mol Ther 21 2013 2136 2147 10.1038/mt.2013.138 23817205
34 Bailey R.M. Armao D. Nagabhushan Kalburgi S. Gray S.J. Development of intrathecal AAV9 gene therapy for giant axonal neuropathy Mol Ther Methods Clin Dev 9 2018 160 171 10.1016/j.omtm.2018.02.005 29766026
35 Piguet F. Sondhi D. Piraud M. Fouquet F. Hackett N.R. Ahouansou O. Correction of brain oligodendrocytes by AAVrh.10 intracerebral gene therapy in metachromatic leukodystrophy mice Hum Gene Ther 23 2012 903 914 10.1089/hum.2012.015 22642214
36 Bradbury A.M. Rafi M.A. Bagel J.H. Brisson B.K. Marshall M.S. Pesayco Salvador J. AAVrh10 gene therapy ameliorates central and peripheral nervous system disease in canine globoid cell leukodystrophy (krabbe disease) Hum Gene Ther 29 2018 785 801 10.1089/hum.2017.151 29316812
37 Francis J.S. Wojtas I. Markov V. Gray S.J. McCown T.J. Samulski R.J. N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase Neurobiol Dis 96 2016 323 334 10.1016/j.nbd.2016.10.001 27717881
38 Hordeaux J. Jeffrey B.A. Jian J. Choudhury G.R. Michalson K. Mitchell T.W. Efficacy and safety of a krabbe disease gene therapy Hum Gene Ther 33 2022 499 517 10.1089/hum.2021.245 35333110
39 Foust K.D. Nurre E. Montgomery C.L. Hernandez A. Chan C.M. Kaspar B.K. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes Nat Biotechnol 27 2009 59 65 10.1038/nbt.1515 19098898
40 Tanguy Y. Biferi M.G. Besse A. Astord S. Cohen-Tannoudji M. Marais T. Systemic AAVrh10 provides higher transgene expression than AAV9 in the brain and the spinal cord of neonatal mice Front Mol Neurosci 8 2015 36 10.3389/fnmol.2015.00036 26283910
41 Zhou K. Han J. Wang Y. Zhang Y. Zhu C. Routes of administration for adeno-associated viruses carrying gene therapies for brain diseases Front Mol Neurosci 15 2022 988914 10.3389/fnmol.2022.988914
42 Surdyka M.M. Figiel M. Retrograde capabilities of adeno-associated virus vectors in the central nervous system Biotechnologia 102 2021 473 478 10.5114/bta.2021.111111 36605599
43 Ball J.B. Frank M.G. Green-Fulgham S.M. Watkins L.R. Use of adeno-associated viruses for transgenic modulation of microglia structure and function: a review of technical considerations and challenges Brain Behav Immun 118 2024 368 379 10.1016/j.bbi.2024.03.005 38471576
44 Hitoshi N. Ken-ichi Y. Jun-ichi M. Efficient selection for high-expression transfectants with a novel eukaryotic vector Gene 108 1991 193 199 10.1016/0378-1119(91)90434-D 1660837
45 Klein R.L. Hamby M.E. Gong Y. Hirko A.C. Wang S. Hughes J.A. Dose and promoter effects of adeno-associated viral vector for green fluorescent protein expression in the rat brain Exp Neurol 176 2002 66 74 10.1006/exnr.2002.7942 12093083
46 Tornøe J. Kusk P. Johansen T.E. Jensen P.R. Generation of a synthetic mammalian promoter library by modification of sequences spacing transcription factor binding sites Gene 297 2002 21 32 10.1016/s0378-1119(02)00878-8 12384282
47 Penaud-Budloo M. Le Guiner C. Nowrouzi A. Toromanoff A. Chérel Y. Chenuaud P. Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle J Virol 82 2008 7875 7885 10.1128/JVI.00649-08 18524821
48 Day J.W. Finkel R.S. Mercuri E. Swoboda K.J. Menier M. van Olden R. Adeno-associated virus serotype 9 antibodies in patients screened for treatment with onasemnogene abeparvovec Mol Ther Methods Clin Dev 21 2021 76 82 10.1016/j.omtm.2021.02.014 33768131
49 Salabarria S.M. Corti M. Coleman K.E. Wichman M.B. Berthy J.A. D'Souza P. Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies J Clin Invest 134 2024 e173510 10.1172/JCI173510
50 Bennett C.F. Krainer A.R. Cleveland D.W. Antisense oligonucleotide therapies for neurodegenerative diseases Annu Rev Neurosci 42 2019 385 406 10.1146/annurev-neuro-070918-050501 31283897
51 Hill S.F. Meisler M.H. Antisense oligonucleotide therapy for neurodevelopmental disorders Dev Neurosci 43 2021 247 252 10.1159/000517686 34412058
52 Lukatela G. Krauss N. Theis K. Selmer T. Gieselmann V. von Figura K. Crystal structure of human arylsulfatase A: the aldehyde function and the metal ion at the active site suggest a novel mechanism for sulfate ester hydrolysis Biochemistry 37 1998 3654 3664 10.1021/bi9714924 9521684
53 Shaimardanova A.A. Chulpanova D.S. Solovyeva V.V. Mullagulova A.I. Kitaeva K.V. Allegrucci C. Metachromatic leukodystrophy: diagnosis, modeling, and treatment approaches Front Med 7 2020 576221 10.3389/fmed.2020.576221
54 Bayever E. Ladisch S. Philippart M. Brill N. Nuwer M. Sparkes R.S. Bone-marrow transplantation for metachromatic leucodystrophy Lancet 2 1985 471 473 10.1016/s0140-6736(85)90402-7 2863494
55 Solders M. Martin D.A. Andersson C. Remberger M. Andersson T. Ringdén O. Hematopoietic SCT: a useful treatment for late metachromatic leukodystrophy Bone Marrow Transplant 49 2014 1046 1051 10.1038/bmt.2014.93 24797185
56 Biffi A. De Palma M. Quattrini A. Del Carro U. Amadio S. Visigalli I. Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells J Clin Invest 113 2004 1118 1129 10.1172/JCI19205 15085191
57 Hess B. Saftig P. Hartmann D. Coenen R. Lüllmann-Rauch R. Goebel H.H. Phenotype of arylsulfatase A-deficient mice: relationship to human metachromatic leukodystrophy Proc Natl Acad Sci U S A 93 1996 14821 14826 10.1073/pnas.93.25.14821 8962139
58 Biffi A. Capotondo A. Fasano S. del Carro U. Marchesini S. Azuma H. Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice J Clin Invest 116 2006 3070 3082 10.1172/JCI28873 17080200
59 Fratantoni J.C. Hall C.W. Neufeld E.F. Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts Science 162 1968 570 572 10.1126/science.162.3853.570 4236721
60 Biffi A. Montini E. Lorioli L. Cesani M. Fumagalli F. Plati T. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy Science 341 2013 1233158 10.1126/science.1233158
61 Sessa M. Lorioli L. Fumagalli F. Acquati S. Redaelli D. Baldoli C. Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial Lancet 388 2016 476 487 10.1016/S0140-6736(16)30374-9 27289174
62 Fumagalli F. Calbi V. Natali Sora M.G. Sessa M. Baldoli C. Rancoita P.M.V. Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access Lancet 399 2022 372 383 10.1016/S0140-6736(21)02017-1 35065785
63 Fumagalli F Calbi V De Mattia F Zambon A Gallo V Recupero S Atidarsagene autotemcel (hematopoietic stem cell-gene therapy) preserves cognitive and motor development in metachromatic leukodystrophy with up to 12 years follow-up [ACMG abstract 005] GIM Open 2 S1 2024 100882
64 Harrington M. Whalley D. Twiss J. Rushton R. Martin S. Huynh L. Insights into the natural history of metachromatic leukodystrophy from interviews with caregivers Orphanet J Rare Dis 14 2019 89 10.1186/s13023-019-1060-2 31036045
65 Groeschel S. Kühl J.-S. Bley A.E. Kehrer C. Weschke B. Döring M. Long-term outcome of allogeneic hematopoietic stem cell transplantation in patients with juvenile metachromatic leukodystrophy compared with nontransplanted control patients JAMA Neurol 73 2016 1133 1140 10.1001/jamaneurol.2016.2067 27400410
66 Al-Saady M. Beerepoot S. Plug B.C. Breur M. Galabova H. Pouwels P.J.W. Neurodegenerative disease after hematopoietic stem cell transplantation in metachromatic leukodystrophy Ann Clin Transl Neurol 10 2023 1146 1159 10.1002/acn3.51796 37212343
67 Consiglio A. Quattrini A. Martino S. Bensadoun J.C. Dolcetta D. Trojani A. In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice Nat Med 7 2001 310 316 10.1038/85454 11231629
68 Penzien J.M. Kappler J. Herschkowitz N. Schuknecht B. Leinekugel P. Propping P. Compound heterozygosity for metachromatic leukodystrophy and arylsulfatase A pseudodeficiency alleles is not associated with progressive neurological disease Am J Hum Genet 52 1993 557 564 8095368
69 Leinekugel P. Michel S. Conzelmann E. Sandhoff K. Quantitative correlation between the residual activity of β-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease Hum Genet 88 1992 513 523 10.1007/BF00219337 1348043
70 Sevin C. Benraiss A. Van Dam D. Bonnin D. Nagels G. Verot L. Intracerebral adeno-associated virus-mediated gene transfer in rapidly progressive forms of metachromatic leukodystrophy Hum Mol Genet 15 2006 53 64 10.1093/hmg/ddi425 16311251
71 Sevin C. Verot L. Benraiss A. Van Dam D. Bonnin D. Nagels G. Partial cure of established disease in an animal model of metachromatic leukodystrophy after intracerebral adeno-associated virus-mediated gene transfer Gene Ther 14 2007 405 414 10.1038/sj.gt.3302883 17093507
72 Zerah M. Piguet F. Colle M.-A. Raoul S. Deschamps J.-Y. Deniaud J. Intracerebral gene therapy using AAVrh.10-hARSA recombinant vector to treat patients with early-onset forms of metachromatic leukodystrophy: preclinical feasibility and safety assessments in nonhuman primates Hum Gene Ther Clin Dev 26 2015 113 124 10.1089/humc.2014.139 25758611
73 Sevin C. Roujeau T. Cartier N. Baugnon T. Adamsbaum C. Piraud M. Intracerebral gene therapy in children with metachromatic leukodystrophy: results of a phase I/II trial Mol Genet Metabol 123 2018 S129
74 Peterson M.R. Cherukuri V. Paulson J.N. Ssentongo P. Kulkarni A.V. Warf B.C. Normal childhood brain growth and a universal sex and anthropomorphic relationship to cerebrospinal fluid J Neurosurg Pediatr 28 2021 458 468 10.3171/2021.2.PEDS201006 34243147
75 Chen X. Lim D.A. Lawlor M.W. Dimmock D. Vite C.H. Lester T. Biodistribution of adeno-associated virus gene therapy following cerebrospinal fluid-directed administration Hum Gene Ther 34 2023 94 111 10.1089/hum.2022.163 36606687
76 Rosenberg J.B. Chen A. De B.P. Dyke J.P. Ballon D.J. Monette S. Safety of direct intraparenchymal AAVrh.10-mediated central nervous system gene therapy for metachromatic leukodystrophy Hum Gene Ther 32 2021 563 580 10.1089/hum.2020.269 33380277
77 Bergner C.G. van der Meer F. Winkler A. Wrzos C. Türkmen M. Valizada E. Microglia damage precedes major myelin breakdown in X-linked adrenoleukodystrophy and metachromatic leukodystrophy Glia 67 2019 1196 1209 10.1002/glia.23598 30980503
78 Reddy A.S. Kim J.H. Hawkins-Salsbury J.A. Macauley S.L. Tracy E.T. Vogler C.A. Bone marrow transplantation augments the effect of brain- and spinal cord-directed adeno-associated virus 2/5 gene therapy by altering inflammation in the murine model of globoid-cell leukodystrophy J Neurosci 31 2011 9945 9957 10.1523/JNEUROSCI.1802-11.2011 21734286
79 Turk B.R. Theda C. Fatemi A. Moser A.B. X-linked adrenoleukodystrophy: pathology, pathophysiology, diagnostic testing, newborn screening and therapies Int J Dev Neurosci 80 2020 52 72 10.1002/jdn.10003 31909500
80 Moser H.W. Mahmood A. Raymond G.V. X-linked adrenoleukodystrophy Nat Clin Pract Neurol 3 2007 140 151 10.1038/ncpneuro0421 17342190
81 Percy A.K. Adrenoleukodystrophy Aminoff M.J. Daroff R.B. Encyclopedia of the neurological sciences second ed. 2014 Academic Press Oxford 65 66 10.1016/B978-0-12-385157-4.00086-5
82 Eichler F.S. Ren J.-Q. Cossoy M. Rietsch A.M. Nagpal S. Moser A.B. Is microglial apoptosis an early pathogenic change in cerebral X-linked adrenoleukodystrophy? Ann Neurol 63 2008 729 742 10.1002/ana.21391 18571777
83 Benhamida S. Pflumio F. Dubart-Kupperschmitt A. Zhao-Emonet J.C. Cavazzana-Calvo M. Rocchiccioli F. Transduced CD34+ cells from adrenoleukodystrophy patients with HIV-derived vector mediate long-term engraftment of NOD/SCID mice Mol Ther 7 2003 317 324 10.1016/s1525-0016(03)00002-9 12668127
84 Asheuer M. Pflumio F. Benhamida S. Dubart-Kupperschmitt A. Fouquet F. Imai Y. Human CD34+ cells differentiate into microglia and express recombinant therapeutic protein Proc Natl Acad Sci U S A 101 2004 3557 3562 10.1073/pnas.0306431101 14990803
85 Raymond G.V. Aubourg P. Paker A. Escolar M. Fischer A. Blanche S. Survival and functional outcomes in boys with cerebral adrenoleukodystrophy with and without hematopoietic stem cell transplantation Biol Blood Marrow Transplant 25 2019 538 548 10.1016/j.bbmt.2018.09.036 30292747
86 Chiesa R. Boelens J.J. Duncan C.N. Kühl J.-S. Sevin C. Kapoor N. Variables affecting outcomes after allogeneic hematopoietic stem cell transplant for cerebral adrenoleukodystrophy Blood Adv 6 2022 1512 1524 10.1182/bloodadvances.2021005294 34781360
87 Cartier N. Hacein-Bey-Abina S. Bartholomae C.C. Veres G. Schmidt M. Kutschera I. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy Science 326 2009 818 823 10.1126/science.1171242 19892975
88 Bougnères P. Hacein-Bey-Abina S. Labik I. Adamsbaum C. Castaignède C. Bellesme C. Long-term follow-up of hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy Hum Gene Ther 32 2021 1260 1269 10.1089/hum.2021.053 33789438
89 Loes D.J. Hite S. Moser H. Stillman A.E. Shapiro E. Lockman L. Adrenoleukodystrophy: a scoring method for brain MR observations AJNR Am J Neuroradiol 15 1994 1761 1766 7847225
90 Moser H.W. Loes D.J. Melhem E.R. Raymond G.V. Bezman L. Cox C.S. X-Linked adrenoleukodystrophy: overview and prognosis as a function of age and brain magnetic resonance imaging abnormality. A study involving 372 patients Neuropediatrics 31 2000 227 239 10.1055/s-2000-9236 11204280
91 Eichler F. Duncan C. Musolino P.L. Orchard P.J. De Oliveira S. Thrasher A.J. Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy N Engl J Med 377 2017 1630 1638 10.1056/NEJMoa1700554 28976817
92 Eichler F.S. Duncan C. Orchard P. De Oliveira S. Thrasher A. Sevin C. Disease stabilization following treatment with elivaldogene autotemcel (eli-cel, lenti-D) gene therapy for the treatment of cerebral adrenoleukodystrophy: interim results from phase 2/3 (ALD-102) and phase 3 (ALD-104) studies (2064) Neurology 96 2021
93 Moser A.B. Kreiter N. Bezman L. Lu S. Raymond G.V. Naidu S. Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls Ann Neurol 45 1999 100 110 10.1002/1531-8249(199901)45:1<100::aid-art16>3.0.co;2-u 9894883
94 Schäfer L. Roicke H. Bergner C.-C. Köhler W. Self-reported quality of life in symptomatic and asymptomatic women with X-linked adrenoleukodystrophy Brain Behav 13 2023 e2878 10.1002/brb3.2878
95 Powers J.M. Deciero D.P. Cox C. Richfield E.K. Ito M. Moser A.B. The dorsal root ganglia in adrenomyeloneuropathy: neuronal atrophy and abnormal mitochondria J Neuropathol Exp Neurol 60 2001 493 501 10.1093/jnen/60.5.493 11379824
96 Gong Y. Laheji F. Berenson A. Li Y. Moser A. Qian A. Role of basal forebrain neurons in adrenomyeloneuropathy in mice and humans Ann Neurol 95 2024 442 458 10.1002/ana.26849 38062617
97 Bey K. Deniaud J. Dubreil L. Joussemet B. Cristini J. Ciron C. Intra-CSF AAV9 and AAVrh10 administration in nonhuman primates: promising routes and vectors for which neurological diseases? Mol Ther Methods Clin Dev 17 2020 771 784 10.1016/j.omtm.2020.04.001 32355866
98 Anderson D, Maguire C, Ng C, Gong Y, Eichler F, Fourcase S, et al. Selection of clinical doses for SBT101, an AAV9-hABCD1 vector for the treatment of adrenomyeloneuropathy [abstract]. Mov Disord n.d.;37..
99 Shieh P.B. Bönnemann C.G. Müller-Felber W. Blaschek A. Dowling J.J. Kuntz N.L. Re: “moving forward after two deaths in a gene therapy trial of myotubular myopathy” by wilson and flotte Hum Gene Ther 31 2020 787 10.1089/hum.2020.217 32777938
100 Bradbury A.M. Bongarzone E.R. Sands M.S. Krabbe disease: new hope for an old disease Neurosci Lett 752 2021 135841 10.1016/j.neulet.2021.135841
101 Hawkins-Salsbury J.A. Parameswar A.R. Jiang X. Schlesinger P.H. Bongarzone E. Ory D.S. Psychosine, the cytotoxic sphingolipid that accumulates in globoid cell leukodystrophy, alters membrane architecture J Lipid Res 54 2013 3303 3311 10.1194/jlr.M039610 24006512
102 Haq E. Giri S. Singh I. Singh A.K. Molecular mechanism of psychosine-induced cell death in human oligodendrocyte cell line J Neurochem 86 2003 1428 1440 10.1046/j.1471-4159.2003.01941.x 12950451
103 Li Y. Xu Y. Benitez B.A. Nagree M.S. Dearborn J.T. Jiang X. Genetic ablation of acid ceramidase in Krabbe disease confirms the psychosine hypothesis and identifies a new therapeutic target Proc Natl Acad Sci U S A 116 2019 20097 20103 10.1073/pnas.1912108116 31527255
104 Del Grosso A. Angella L. Tonazzini I. Moscardini A. Giordano N. Caleo M. Dysregulated autophagy as a new aspect of the molecular pathogenesis of Krabbe disease Neurobiol Dis 129 2019 195 207 10.1016/j.nbd.2019.05.011 31108173
105 Reiter C.R. Rebiai R. Kwak A. Marshall J. Wozniak D. Scesa G. The pathogenic sphingolipid psychosine is secreted in extracellular vesicles in the brain of a mouse model of krabbe disease ASN Neuro 14 2022 17590914221087817 10.1177/17590914221087817
106 Smith B.R. Santos M.B. Marshall M.S. Cantuti-Castelvetri L. Lopez-Rosas A. Li G. Neuronal inclusions of α-synuclein contribute to the pathogenesis of Krabbe disease J Pathol 232 2014 509 521 10.1002/path.4328 24415155
107 Hatton C. Ghanem S.S. Koss D.J. Abdi I.Y. Gibbons E. Guerreiro R. Prion-like α-synuclein pathology in the brain of infants with Krabbe disease Brain 145 2022 1257 1263 10.1093/brain/awac002 34999780
108 Komatsuzaki S. Zielonka M. Mountford W.K. Kölker S. Hoffmann G.F. Garbade S.F. Clinical characteristics of 248 patients with Krabbe disease: quantitative natural history modeling based on published cases Genet Med 21 2019 2208 2215 10.1038/s41436-019-0480-7 30899093
109 Siddiqi Z.A. Sanders D.B. Massey J.M. Peripheral neuropathy in Krabbe disease: electrodiagnostic findings Neurology 67 2006 263 267 10.1212/01.wnl.0000230153.34613.84 16864819
110 Zhang H. Yang B. Mu X. Ahmed S.S. Su Q. He R. Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system Mol Ther 19 2011 1440 1448 10.1038/mt.2011.98 21610699
111 Rafi M.A. Rao H.Z. Luzi P. Luddi A. Curtis M.T. Wenger D.A. Intravenous injection of AAVrh10-GALC after the neonatal period in twitcher mice results in significant expression in the central and peripheral nervous systems and improvement of clinical features Mol Genet Metabol 114 2015 459 466 10.1016/j.ymgme.2014.12.300
112 Lin D. Fantz C.R. Levy B. Rafi M.A. Vogler C. Wenger D.A. AAV2/5 vector expressing galactocerebrosidase ameliorates CNS disease in the murine model of globoid-cell leukodystrophy more efficiently than AAV2 Mol Ther 12 2005 422 430 10.1016/j.ymthe.2005.04.019 15996520
113 Hawkins-Salsbury J.A. Shea L. Jiang X. Hunter D.A. Guzman A.M. Reddy A.S. Mechanism-based combination treatment dramatically increases therapeutic efficacy in murine globoid cell leukodystrophy J Neurosci 35 2015 6495 6505 10.1523/JNEUROSCI.4199-14.2015 25904800
114 Li Y. Miller C.A. Shea L.K. Jiang X. Guzman M.A. Chandler R.J. Enhanced efficacy and increased long-term toxicity of CNS-directed, AAV-based combination therapy for krabbe disease Mol Ther 29 2021 691 701 10.1016/j.ymthe.2020.12.031 33388420
115 Weinstock N.I. Shin D. Dhimal N. Hong X. Irons E.E. Silvestri N.J. Macrophages expressing GALC improve peripheral krabbe disease by a mechanism independent of cross-correction Neuron 107 2020 65 81.e9 10.1016/j.neuron.2020.03.031 32375064
116 Lin D. Donsante A. Macauley S. Levy B. Vogler C. Sands M.S. Central nervous system-directed AAV2/5-mediated gene therapy synergizes with bone marrow transplantation in the murine model of globoid-cell leukodystrophy Mol Ther 15 2007 44 52 10.1038/sj.mt.6300026 17164774
117 Rafi M.A. Luzi P. Wenger D.A. Can early treatment of twitcher mice with high dose AAVrh10-GALC eliminate the need for BMT? Bioimpacts 11 2021 135 146 10.34172/bi.2021.21 33842284
118 Bradbury A.M. Bagel J. Swain G. Miyadera K. Pesayco J.P. Assenmacher C.-A. Combination HSCT and intravenous AAV-mediated gene therapy in a canine model proves pivotal for translation of Krabbe disease therapy Mol Ther 32 2024 44 58 10.1016/j.ymthe.2023.11.014 37952085
119 Escolar M. Lugt M.V. Poe M. Greco M. Werling K. De Silva E. P014: first-in-human phase 1/2 trial of intravenous FBX-101 with cord blood transplantation increases GALC, brain and motor development in infantile Krabbe Genet Med 1 2023 100024
120 Hinderer C. Katz N. Dyer C. Goode T. Johansson J. Bell P. Translational feasibility of lumbar puncture for intrathecal AAV administration Mol Ther Methods Clin Dev 17 2020 969 974 10.1016/j.omtm.2020.04.012 32420410
121 Kofler J. Beltran-Quintero M.L. Rugari A. Zuccoli G. Klotz S. Escolar M.L. Improved brain pathology and progressive peripheral neuropathy in a 15 Year old survivor of infantile krabbe disease treated with umbilical cord transplantation Front Mol Neurosci 15 2022 888231 10.3389/fnmol.2022.888231
122 Chakraborty G. Mekala P. Yahya D. Wu G. Ledeen R.W. Intraneuronal N-acetylaspartate supplies acetyl groups for myelin lipid synthesis: evidence for myelin-associated aspartoacylase J Neurochem 78 2001 736 745 10.1046/j.1471-4159.2001.00456.x 11520894
123 Traka M. Wollmann R.L. Cerda S.R. Dugas J. Barres B.A. Popko B. Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS J Neurosci 28 2008 11537 11549 10.1523/JNEUROSCI.1490-08.2008 18987190
124 Bley A. Denecke J. Kohlschütter A. Schön G. Hischke S. Guder P. The natural history of Canavan disease: 23 new cases and comparison with patients from literature Orphanet J Rare Dis 16 2021 227 10.1186/s13023-020-01659-3 34011350
125 Traeger E.C. Rapin I. The clinical course of Canavan disease Pediatr Neurol 18 1998 207 212 10.1016/s0887-8994(97)00185-9 9568915
126 Leone P. Janson C.G. Bilaniuk L. Wang Z. Sorgi F. Huang L. Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease Ann Neurol 48 2000 27 38 10.1002/1531-8249(200007)48:1<27::aid-ana6>3.0.co;2-6 10894213
127 Leone P. Shera D. McPhee S.W.J. Francis J.S. Kolodny E.H. Bilaniuk L.T. Long-term follow-up after gene therapy for canavan disease Sci Transl Med 4 2012 165ra163 10.1126/scitranslmed.3003454
128 Powell S.K. Khan N. Parker C.L. Samulski R.J. Matsushima G. Gray S.J. Characterization of a novel adeno-associated viral vector with preferential oligodendrocyte tropism Gene Ther 23 2016 807 814 10.1038/gt.2016.62 27628693
129 Francis J.S. Markov V. Wojtas I.D. Gray S. McCown T. Samulski R.J. Preclinical biodistribution, tropism, and efficacy of oligotropic AAV/Olig001 in a mouse model of congenital white matter disease Mol Ther Methods Clin Dev 20 2021 520 534 10.1016/j.omtm.2021.01.009 33614826
130 Matalon R. Surendran S. Rady P.L. Quast M.J. Campbell G.A. Matalon K.M. Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease Mol Ther 7 2003 580 587 10.1016/s1525-0016(03)00066-2 12718900
131 Eichler F. Nagy A. Laforet G. Andonian H. Kinane B. Townsend E. Initial biomarker and clinical findings from the CANaspire canavan disease gene therapy trial: exploration of connections between NAA and disease severity 2023
132 Kang J.J. Liu I.Y. Wang M.B. Srivatsan E.S. A review of gigaxonin mutations in giant axonal neuropathy (GAN) and cancer Hum Genet 135 2016 675 684 10.1007/s00439-016-1659-5 27023907
133 Chen P.-H. Hu J. Wu J. Huynh D.T. Smith T.J. Pan S. Gigaxonin glycosylation regulates intermediate filament turnover and may impact giant axonal neuropathy etiology or treatment JCI Insight 5 2020 e127751 10.1172/jci.insight.127751 127751
134 Bharucha-Goebel D.X. Norato G. Saade D. Paredes E. Biancavilla V. Donkervoort S. Giant axonal neuropathy: cross-sectional analysis of a large natural history cohort Brain 144 2021 3239 3250 10.1093/brain/awab179 34114613
135 Demir E. Bomont P. Erdem S. Cavalier L. Demirci M. Kose G. Giant axonal neuropathy: clinical and genetic study in six cases J Neurol Neurosurg Psychiatry 76 2005 825 832 10.1136/jnnp.2003.035162 15897506
136 Bruno C. Bertini E. Federico A. Tonoli E. Lispi M.L. Cassandrini D. Clinical and molecular findings in patients with giant axonal neuropathy (GAN) Neurology 62 2004 13 16 10.1212/01.wnl.0000101676.41505.a7 14718689
137 Takebe Y. Koide N. Takahashi G. Giant axonal neuropathy: report of two siblings with endocrinological and histological studies Neuropediatrics 12 1981 392 404 10.1055/s-2008-1059670 6801537
138 Ionasescu V. Searby C. Rubenstein P. Sandra A. Cancilla P. Robillard J. Giant axonal neuropathy: normal protein composition of neurofilaments J Neurol Neurosurg Psychiatry 46 1983 551 554 10.1136/jnnp.46.6.551 6410005
139 Mohri I. Taniike M. Yoshikawa H. Higashiyama M. Itami S. Okada S. A case of giant axonal neuropathy showing focal aggregation and hypophosphorylation of intermediate filaments Brain Dev 20 1998 594 597 10.1016/s0387-7604(98)00056-4 9865543
140 Kumar K. Barre P. Nigro M. Jones M.Z. Giant axonal neuropathy: clinical, electrophysiologic, and neuropathologic features in two siblings J Child Neurol 5 1990 229 234 10.1177/088307389000500316 2168911
141 Houlden H. Groves M. Miedzybrodzka Z. Roper H. Willis T. Winer J. New mutations, genotype phenotype studies and manifesting carriers in giant axonal neuropathy J Neurol Neurosurg Psychiatry 78 2007 1267 1270 10.1136/jnnp.2007.118968 17578852
142 Hoffman W.H. Carroll J.E. Perry G.Y. Hartlage P.L. Kaminer S.J. Flowers N.C. Giant axonal neuropathy in a child with insulin-dependent diabetes mellitus J Child Neurol 10 1995 250 253 10.1177/088307389501000322 7642902
143 Yang Y. Allen E. Ding J. Wang W. Giant axonal neuropathy Cell Mol Life Sci 64 2007 601 609 10.1007/s00018-007-6396-4 17256086
144 Roth L.A. Johnson-Kerner B.L. Marra J.D. LaMarca N.H. Sproule D.M. The absence of curly hair is associated with a milder phenotype in Giant Axonal Neuropathy Neuromuscul Disord 24 2014 48 55 10.1016/j.nmd.2013.06.007 23890932
145 Mussche S. Devreese B. Nagabhushan Kalburgi S. Bachaboina L. Fox J.C. Shih H.-J. Restoration of cytoskeleton homeostasis after gigaxonin gene transfer for giant axonal neuropathy Hum Gene Ther 24 2013 209 219 10.1089/hum.2012.107 23316953
146 Mahammad S. Murthy S.N.P. Didonna A. Grin B. Israeli E. Perrot R. Giant axonal neuropathy-associated gigaxonin mutations impair intermediate filament protein degradation J Clin Invest 123 2013 1964 1975 10.1172/JCI66387 23585478
147 Johnson-Kerner B.L. Ahmad F.S. Diaz A.G. Greene J.P. Gray S.J. Samulski R.J. Intermediate filament protein accumulation in motor neurons derived from giant axonal neuropathy iPSCs rescued by restoration of gigaxonin Hum Mol Genet 24 2015 1420 1431 10.1093/hmg/ddu556 25398950
148 Ding J. Allen E. Wang W. Valle A. Wu C. Nardine T. Gene targeting of GAN in mouse causes a toxic accumulation of microtubule-associated protein 8 and impaired retrograde axonal transport Hum Mol Genet 15 2006 1451 1463 10.1093/hmg/ddl069 16565160
149 Dequen F. Bomont P. Gowing G. Cleveland D.W. Julien J.-P. Modest loss of peripheral axons, muscle atrophy and formation of brain inclusions in mice with targeted deletion of gigaxonin exon 1 J Neurochem 107 2008 253 264 10.1111/j.1471-4159.2008.05601.x 18680552
150 Cleveland D.W. Yamanaka K. Bomont P. Gigaxonin controls vimentin organization through a tubulin chaperone-independent pathway Hum Mol Genet 18 2009 1384 1394 10.1093/hmg/ddp044 19168853
151 Bharucha-Goebel D.X. Todd J.J. Saade D. Norato G. Jain M. Lehky T. Intrathecal gene therapy for giant axonal neuropathy N Engl J Med 390 2024 1092 1104 10.1056/NEJMoa2307952 38507752
152 Leal A.F. Benincore-Flórez E. Solano-Galarza D. Garzón Jaramillo R.G. Echeverri-Peña O.Y. Suarez D.A. GM2 gangliosidoses: clinical features, pathophysiological aspects, and current therapies Int J Mol Sci 21 2020 6213 10.3390/ijms21176213 32867370
153 Haberland C. Brunngraber E. Witting L. Brown B. The white matter in GM2 gangliosidosis Acta Neuropathol 24 1973 43 55 10.1007/BF00691417 4267001
154 Virgolini M.J. Feliziani C. Cambiasso M.J. Lopez P.H. Bollo M. Neurite atrophy and apoptosis mediated by PERK signaling after accumulation of GM2-ganglioside Biochim Biophys Acta Mol Cell Res 1866 2019 225 239 10.1016/j.bbamcr.2018.10.014 30389374
155 d'Azzo A. Tessitore A. Sano R. Gangliosides as apoptotic signals in ER stress response Cell Death Differ 13 2006 404 414 10.1038/sj.cdd.4401834 16397581
156 Bley A.E. Giannikopoulos O.A. Hayden D. Kubilus K. Tifft C.J. Eichler F.S. Natural history of infantile G(M2) gangliosidosis Pediatrics 128 2011 e1233 e1241 10.1542/peds.2011-0078 22025593
157 Smith N.J. Winstone A.M. Stellitano L. Cox T.M. Verity C.M. GM2 gangliosidosis in a UK study of children with progressive neurodegeneration: 73 cases reviewed Dev Med Child Neurol 54 2012 176 182 10.1111/j.1469-8749.2011.04160.x 22115551
158 Maegawa G.H.B. Stockley T. Tropak M. Banwell B. Blaser S. Kok F. The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported Pediatrics 118 2006 e1550 e1562 10.1542/peds.2006-0588 17015493
159 Neudorfer O. Pastores G.M. Zeng B.J. Gianutsos J. Zaroff C.M. Kolodny E.H. Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients Genet Med 7 2005 119 123 10.1097/01.gim.0000154300.84107.75 15714079
160 Guidotti J.E. Mignon A. Haase G. Caillaud C. McDonell N. Kahn A. Adenoviral gene therapy of the Tay-Sachs disease in hexosaminidase A-deficient knock-out mice Hum Mol Genet 8 1999 831 838 10.1093/hmg/8.5.831 10196372
161 Arfi A. Bourgoin C. Basso L. Emiliani C. Tancini B. Chigorno V. Bicistronic lentiviral vector corrects beta-hexosaminidase deficiency in transduced and cross-corrected human Sandhoff fibroblasts Neurobiol Dis 20 2005 583 593 10.1016/j.nbd.2005.04.017 15953731
162 Itakura T. Kuroki A. Ishibashi Y. Tsuji D. Kawashita E. Higashine Y. Inefficiency in GM2 ganglioside elimination by human lysosomal beta-hexosaminidase beta-subunit gene transfer to fibroblastic cell line derived from Sandhoff disease model mice Biol Pharm Bull 29 2006 1564 1569 10.1248/bpb.29.1564 16880605
163 Sango K. Yamanaka S. Hoffmann A. Okuda Y. Grinberg A. Westphal H. Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism Nat Genet 11 1995 170 176 10.1038/ng1095-170 7550345
164 Phaneuf D. Wakamatsu N. Huang J.-Q. Borowski A. Peterson A.C. Fortunato S.R. Dramatically different phenotypes in mouse models of human tay-sachs and sandhoff diseases Hum Mol Genet 5 1996 1 14 10.1093/hmg/5.1.1 8789434
165 Cachón-González M.B. Wang S.Z. Lynch A. Ziegler R. Cheng S.H. Cox T.M. Effective gene therapy in an authentic model of Tay-Sachs-related diseases Proc Natl Acad Sci USA 103 2006 10373 10378 10.1073/pnas.0603765103 16801539
166 Cachón-González M.B. Wang S.Z. McNair R. Bradley J. Lunn D. Ziegler R. Gene transfer corrects acute GM2 gangliosidosis—potential therapeutic contribution of perivascular enzyme flow Mol Ther 20 2012 1489 1500 10.1038/mt.2012.44 22453766
167 Hadaczek P. Mirek H. Bringas J. Cunningham J. Bankiewicz K. Basic fibroblast growth factor enhances transduction, distribution, and axonal transport of adeno-associated virus type 2 vector in rat brain Hum Gene Ther 15 2004 469 479 10.1089/10430340460745793 15144577
168 Kaspar B.K. Lladó J. Sherkat N. Rothstein J.D. Gage F.H. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model Science 301 2003 839 842 10.1126/science.1086137 12907804
169 Bradbury A.M. Cochran J.N. McCurdy V.J. Johnson A.K. Brunson B.L. Gray-Edwards H. Therapeutic response in feline sandhoff disease despite immunity to intracranial gene therapy Mol Ther 21 2013 1306 1315 10.1038/mt.2013.86 23689599
170 Halder S. Van Vliet K. Smith J.K. Duong T.T.P. McKenna R. Wilson J.M. Structure of neurotropic adeno-associated virus AAVrh.8 J Struct Biol 192 2015 21 36 10.1016/j.jsb.2015.08.017 26334681
171 McCurdy V.J. Rockwell H.E. Arthur J.R. Bradbury A.M. Johnson A.K. Randle A.N. Widespread correction of central nervous system disease after intracranial gene therapy in a feline model of Sandhoff disease Gene Ther 22 2015 181 189 10.1038/gt.2014.108 25474439
172 Bradbury A.M. Gray-Edwards H.L. Shirley J.L. McCurdy V.J. Colaco A.N. Randle A.N. Biomarkers for disease progression and AAV therapeutic efficacy in feline Sandhoff disease Exp Neurol 263 2015 102 112 10.1016/j.expneurol.2014.09.020 25284324
173 Torres P.A. Zeng B.J. Porter B.F. Alroy J. Horak F. Horak J. Tay-Sachs disease in Jacob sheep Mol Genet Metabol 101 2010 357 363 10.1016/j.ymgme.2010.08.006
174 Story B. Taghian T. Gallagher J. Koehler J. Taylor A. Randle A. Natural history of tay-sachs disease in sheep Mol Genet Metabol 134 2021 164 174 10.1016/j.ymgme.2021.08.009
175 Gray-Edwards H.L. Hubbard S.M. Randle A.E. Hwang M. Bradbury A.M. McCurdy V.J. Amelioration of neurologic disease after AAV-gene therapy in a sheep model of tay-sachs disease Mol Ther 21 2013 S17
176 Gray-Edwards H.L. Randle A.N. Maitland S.A. Benatti H.R. Hubbard S.M. Canning P.F. Adeno-associated virus gene therapy in a sheep model of tay–sachs disease Hum Gene Ther 29 2018 312 326 10.1089/hum.2017.163 28922945
177 Flotte T.R. Cataltepe O. Puri A. Batista A.R. Moser R. McKenna-Yasek D. AAV gene therapy for Tay-Sachs disease Nat Med 28 2022 251 259 10.1038/s41591-021-01664-4 35145305
178 Wippold F.J. Perry A. Lennerz J. Neuropathology for the neuroradiologist: Rosenthal fibers AJNR Am J Neuroradiol 27 2006 958 961 16687524
179 Sosunov A.A. McKhann G.M. Goldman J.E. The origin of Rosenthal fibers and their contributions to astrocyte pathology in Alexander disease Acta Neuropathol Commun 5 2017 27 10.1186/s40478-017-0425-9 28359321
180 Moody L.R. Barrett-Wilt G.A. Sussman M.R. Messing A. Glial fibrillary acidic protein exhibits altered turnover kinetics in a mouse model of Alexander disease J Biol Chem 292 2017 5814 5824 10.1074/jbc.M116.772020 28223355
181 Messing A. Alexander disease Handb Clin Neurol 148 2018 693 700 10.1016/B978-0-444-64076-5.00044-2 29478608
182 Hagemann T.L. Powers B. Lin N.-H. Mohamed A.F. Dague K.L. Hannah S.C. Antisense therapy in a rat model of Alexander disease reverses GFAP pathology, white matter deficits, and motor impairment Sci Transl Med 13 2021 eabg4711 10.1126/scitranslmed.abg4711
183 Messing A. Head M.W. Galles K. Galbreath E.J. Goldman J.E. Brenner M. Fatal encephalopathy with astrocyte inclusions in GFAP transgenic mice Am J Pathol 152 1998 391 398 9466565
184 Olabarria M. Putilina M. Riemer E.C. Goldman J.E. Astrocyte pathology in Alexander disease causes a marked inflammatory environment Acta Neuropathol 130 2015 469 486 10.1007/s00401-015-1469-1 26296699
185 Tian R. Wu X. Hagemann T.L. Sosunov A.A. Messing A. McKhann G.M. Alexander disease mutant glial fibrillary acidic protein compromises glutamate transport in astrocytes J Neuropathol Exp Neurol 69 2010 335 345 10.1097/NEN.0b013e3181d3cb52 20448479
186 Wang L. Colodner K.J. Feany M.B. Protein misfolding and oxidative stress promote glial-mediated neurodegeneration in an Alexander disease model J Neurosci 31 2011 2868 2877 10.1523/JNEUROSCI.3410-10.2011 21414908
187 Prust M. Wang J. Morizono H. Messing A. Brenner M. Gordon E. GFAP mutations, age at onset, and clinical subtypes in Alexander disease Neurology 77 2011 1287 1294 10.1212/WNL.0b013e3182309f72 21917775
188 Kuhn J. Cascella M. Alexander disease. StatPearls, treasure island (FL) 2024 StatPearls Publishing
189 Helm J. Schöls L. Hauser S. Towards personalized allele-specific antisense oligonucleotide therapies for toxic gain-of-function neurodegenerative diseases Pharmaceutics 14 2022 1708 10.3390/pharmaceutics14081708 36015334
190 Hagemann T.L. Powers B. Mazur C. Kim A. Wheeler S. Hung G. Antisense suppression of glial fibrillary acidic protein as a treatment for Alexander disease Ann Neurol 83 2018 27 39 10.1002/ana.25118 29226998
191 Hagemann T.L. Connor J.X. Messing A. Alexander disease-associated glial fibrillary acidic protein mutations in mice induce Rosenthal fiber formation and a white matter stress response J Neurosci 26 2006 11162 11173 10.1523/JNEUROSCI.3260-06.2006 17065456
192 Jafar-nejad P. Powers B. Soriano A. Zhao H. Norris D.A. Matson J. The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration Nucleic Acids Res 49 2021 657 673 10.1093/nar/gkaa1235 33367834
193 Elitt M.S. Tesar P.J. Pelizaeus-Merzbacher disease: on the cusp of myelin medicine Trends Mol Med 30 2024 459 470 10.1016/j.molmed.2024.03.005 38582621
194 Inoue K. Cellular pathology of pelizaeus-merzbacher disease involving chaperones associated with endoplasmic reticulum stress Front Mol Biosci 4 2017 7 10.3389/fmolb.2017.00007 28286750
195 Southwood C.M. Garbern J. Jiang W. Gow A. The unfolded protein response modulates disease severity in Pelizaeus-Merzbacher disease Neuron 36 2002 585 596 10.1016/s0896-6273(02)01045-0 12441049
196 Gow A. Southwood C.M. Lazzarini R.A. Disrupted proteolipid protein trafficking results in oligodendrocyte apoptosis in an animal model of Pelizaeus-Merzbacher disease J Cell Biol 140 1998 925 934 10.1083/jcb.140.4.925 9472043
197 Inoue K. Pelizaeus-merzbacher disease: molecular and cellular pathologies and associated phenotypes Adv Exp Med Biol 1190 2019 201 216 10.1007/978-981-32-9636-7_13 31760646
198 Grossi S. Regis S. Biancheri R. Mort M. Lualdi S. Bertini E. Molecular genetic analysis of the PLP1 gene in 38 families with PLP1-related disorders: identification and functional characterization of 11 novel PLP1 mutations Orphanet J Rare Dis 6 2011 40 10.1186/1750-1172-6-40 21679407
199 Phillips R.J.S. Jimpy, a new totally sex-linked gene in the house mouse Z Vererbungslehre 86 1954 322 326 10.1007/BF00312228
200 Sidman R.L. Dickie M.M. Appel S.H. Mutant mice (quaking and jimpy) with deficient myelination in the central nervous system Science 144 1964 309 311 10.1126/science.144.3616.309 14169723
201 Nave K.A. Lai C. Bloom F.E. Milner R.J. Jimpy mutant mouse: a 74-base deletion in the mRNA for myelin proteolipid protein and evidence for a primary defect in RNA splicing Proc Natl Acad Sci U S A 83 1986 9264 9268 3466187
202 Elitt M.S. Barbar L. Shick H.E. Powers B.E. Maeno-Hikichi Y. Madhavan M. Suppression of proteolipid protein rescues Pelizaeus-Merzbacher disease Nature 585 2020 397 403 10.1038/s41586-020-2494-3 32610343
203 Hacein-Bey-Abina S. von Kalle C. Schmidt M. Le Deist F. Wulffraat N. McIntyre E. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency N Engl J Med 348 2003 255 256 10.1056/NEJM200301163480314 12529469
204 Hacein-Bey-Abina S. Garrigue A. Wang G.P. Soulier J. Lim A. Morillon E. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1 J Clin Invest 118 2008 3132 3142 10.1172/JCI35700 18688285
205 Howe S.J. Mansour M.R. Schwarzwaelder K. Bartholomae C. Hubank M. Kempski H. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients J Clin Invest 118 2008 3143 3150 10.1172/JCI35798 18688286
206 Gupta A.O. Raymond G. Pierpont E.I. Kemp S. McIvor R.S. Rayannavar A. Treatment of cerebral adrenoleukodystrophy: allogeneic transplantation and lentiviral gene therapy Expet Opin Biol Ther 22 2022 1151 1162 10.1080/14712598.2022.2124857
207 Birdwell C. Fiskus W. Kadia T.M. DiNardo C.D. Mill C.P. Bhalla K.N. EVI1 dysregulation: impact on biology and therapy of myeloid malignancies Blood Cancer J 11 2021 64 10.1038/s41408-021-00457-9 33753715
208 Lux S. Milsom M.D. EVI1-mediated programming of normal and malignant hematopoiesis Hemasphere 7 2023 e959 10.1097/HS9.0000000000000959 37810550
209 Kustikova O.S. Schwarzer A. Stahlhut M. Brugman M.H. Neumann T. Yang M. Activation of Evi1 inhibits cell cycle progression and differentiation of hematopoietic progenitor cells Leukemia 27 2013 1127 1138 10.1038/leu.2012.355 23212151
210 Biffi A. Bartolomae C.C. Cesana D. Cartier N. Aubourg P. Ranzani M. Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection Blood 117 2011 5332 5339 10.1182/blood-2010-09-306761 21403130
211 Wunderlich M. Chou F.-S. Sexton C. Presicce P. Chougnet C.A. Aliberti J. Improved multilineage human hematopoietic reconstitution and function in NSGS mice PLoS One 13 2018 e0209034 10.1371/journal.pone.0209034
212 Soerensen J.F. Aggerholm A. Rosenberg C.A. Bill M. Kerndrup G.B. Ebbesen L.H. Clonal evolution in patients developing therapy-related myeloid neoplasms following autologous stem cell transplantation Bone Marrow Transplant 57 2022 460 465 10.1038/s41409-022-01567-z 35027675
213 Nakai H. Storm T.A. Kay M.A. Recruitment of single-stranded recombinant adeno-associated virus vector genomes and intermolecular recombination are responsible for stable transduction of liver in vivo J Virol 74 2000 9451 9463 10.1128/jvi.74.20.9451-9463.2000 11000214
214 Gonçalves M.A. Adeno-associated virus: from defective virus to effective vector Virol J 2 2005 43 10.1186/1743-422X-2-43 15877812
215 Nakai H. Montini E. Fuess S. Storm T.A. Grompe M. Kay M.A. AAV serotype 2 vectors preferentially integrate into active genes in mice Nat Genet 34 2003 297 302 10.1038/ng1179 12778174
216 Chandler R.J. Sands M.S. Venditti C.P. Recombinant adeno-associated viral integration and genotoxicity: insights from animal models Hum Gene Ther 28 2017 314 322 10.1089/hum.2017.009 28293963
217 Nguyen G.N. Everett J.K. Kafle S. Roche A.M. Raymond H.E. Leiby J. A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells Nat Biotechnol 39 2021 47 55 10.1038/s41587-020-0741-7 33199875
218 Greig J.A. Martins K.M. Breton C. Lamontagne R.J. Zhu Y. He Z. Integrated vector genomes may contribute to long-term expression in primate liver after AAV administration Nat Biotechnol 2023 10.1038/s41587-023-01974-7
219 Nault J.-C. Datta S. Imbeaud S. Franconi A. Mallet M. Couchy G. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas Nat Genet 47 2015 1187 1193 10.1038/ng.3389 26301494
220 La Bella T. Imbeaud S. Peneau C. Mami I. Datta S. Bayard Q. Adeno-associated virus in the liver: natural history and consequences in tumour development Gut 69 2020 737 747 10.1136/gutjnl-2019-318281 31375600
221 Donsante A. Miller D.G. Li Y. Vogler C. Brunt E.M. Russell D.W. AAV vector integration sites in mouse hepatocellular carcinoma Science 317 2007 477 10.1126/science.1142658 17656716
222 Sabatino D.E. Bushman F.D. Chandler R.J. Crystal R.G. Davidson B.L. Dolmetsch R. Evaluating the state of the science for adeno-associated virus integration: an integrated perspective Mol Ther 30 2022 2646 2663 10.1016/j.ymthe.2022.06.004 35690906
223 Schmidt M. Foster G.R. Coppens M. Thomsen H. Dolmetsch R. Heijink L. Molecular evaluation and vector integration analysis of HCC complicating AAV gene therapy for hemophilia B Blood Adv 7 2023 4966 4969 10.1182/bloodadvances.2023009876 37352263
224 Mendell J.R. Al-Zaidy S. Shell R. Arnold W.D. Rodino-Klapac L.R. Prior T.W. Single-dose gene-replacement therapy for spinal muscular atrophy N Engl J Med 377 2017 1713 1722 10.1056/NEJMoa1706198 29091557
225 Deng J. Zhang J. Shi K. Liu Z. Drug development progress in duchenne muscular dystrophy Front Pharmacol 13 2022 950651 10.3389/fphar.2022.950651
226 Morales L. Gambhir Y. Bennett J. Stedman H.H. Broader implications of progressive liver dysfunction and lethal sepsis in two boys following systemic high-dose AAV Mol Ther 28 2020 1753 1755 10.1016/j.ymthe.2020.07.009 32710826
227 Hordeaux J. Lamontagne R.J. Song C. Buchlis G. Dyer C. Buza E.L. High-dose systemic adeno-associated virus vector administration causes liver and sinusoidal endothelial cell injury Mol Ther 32 2024 952 968 10.1016/j.ymthe.2024.02.002 38327046
228 Schwotzer N. Sissy C.E. Desguerre I. Frémeaux-Bacchi V. Servais L. Fakhouri F. Thrombotic microangiopathy as an emerging complication of viral vector–based gene therapy Kidney International Reports 2024 10.1016/j.ekir.2024.04.024 0
229 Dunkelberger J.R. Song W.-C. Complement and its role in innate and adaptive immune responses Cell Res 20 2010 34 50 10.1038/cr.2009.139 20010915
230 Hamilton B.A. Wright J.F. Challenges posed by immune responses to AAV vectors: addressing root causes Front Immunol 12 2021 675897 10.3389/fimmu.2021.675897
231 Zaiss A.K. Cotter M.J. White L.R. Clark S.A. Wong N.C.W. Holers V.M. Complement is an essential component of the immune response to adeno-associated virus vectors J Virol 82 2008 2727 2740 10.1128/JVI.01990-07 18199646
232 Zhang R. Zhou M. Qi J. Miao W. Zhang Z. Wu D. Efficacy and safety of eculizumab in the treatment of transplant-associated thrombotic microangiopathy: a systematic review and meta-analysis Front Immunol 11 2021 564647 10.3389/fimmu.2020.564647
233 Stanton A.C. Lagerborg K.A. Tellez L. Krunnfusz A. King E.M. Ye S. Systemic administration of novel engineered AAV capsids facilitates enhanced transgene expression in the macaque CNS Méd 4 2023 31 50.e8 10.1016/j.medj.2022.11.002 36417917
234 Okada Y. Hosoi N. Matsuzaki Y. Fukai Y. Hiraga A. Nakai J. Development of microglia-targeting adeno-associated viral vectors as tools to study microglial behavior in vivo Commun Biol 5 2022 1224 10.1038/s42003-022-04200-3 36369525
235 Young A. Neumann B. Segel M. Chen C.Z.-Y. Tourlomousis P. Franklin R.J.M. Targeted evolution of adeno-associated virus capsids for systemic transgene delivery to microglia and tissue-resident macrophages Proc Natl Acad Sci U S A 120 2023 e2302997120 10.1073/pnas.2302997120
236 Lin R. Zhou Y. Yan T. Wang R. Li H. Wu Z. Directed evolution of adeno-associated virus for efficient gene delivery to microglia Nat Methods 19 2022 976 985 10.1038/s41592-022-01547-7 35879607
237 Pulicherla N. Shen S. Yadav S. Debbink K. Govindasamy L. Agbandje-McKenna M. Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer Mol Ther 19 2011 1070 1078 10.1038/mt.2011.22 21364538
238 Tarantal A.F. Lee C.C.I. Martinez M.L. Asokan A. Samulski R.J. Systemic and persistent muscle gene expression in rhesus monkeys with a liver de-targeted adeno-associated virus vector Hum Gene Ther 28 2017 385 391 10.1089/hum.2016.130 28125921
239 Piechnik M. Sawamoto K. Ohnishi H. Kawamoto N. Ago Y. Tomatsu S. Evading the AAV immune response in mucopolysaccharidoses Int J Mol Sci 21 2020 3433 10.3390/ijms21103433 32414007
240 Earley J. Piletska E. Ronzitti G. Piletsky S. Evading and overcoming AAV neutralization in gene therapy Trends Biotechnol 41 2023 836 845 10.1016/j.tibtech.2022.11.006 36503641
241 Zheng Y. Li Y. Zhou K. Li T. VanDusen N.J. Hua Y. Precise genome-editing in human diseases: mechanisms, strategies and applications Signal Transduct Targeted Ther 9 2024 47 10.1038/s41392-024-01750-2
